var title_f41_15_42224="Calcaneus fracture";
var content_f41_15_42224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Calcaneus fracture in a toddler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fracture of the calcaneus in a toddler was not seen on the initial x-ray (A) but was visible on subsequent x-rays (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42224=[""].join("\n");
var outline_f41_15_42224=null;
var title_f41_15_42225="Osgood-Schlatter radiographic findings";
var content_f41_15_42225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Osgood-Schlatter radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the soft tissue swelling anterior to the tibial tuberosity (before ossification).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Kienstra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42225=[""].join("\n");
var outline_f41_15_42225=null;
var title_f41_15_42226="Echo assessment rt ventricle1";
var content_f41_15_42226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75412%7EOBGYN%2F57522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75412%7EOBGYN%2F57522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Echocardiographic assessment of right ventricle in an infant with congenital diaphragmatic hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 182px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prolonged elevated pulmonary vascular resistance leads to a dilated, non-compliant right ventricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Holly L Hedrick, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Echocardiographic estimate of right ventricular pressure in an infant with congenital diaphragmatic hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimates of right ventricular pressure are obtained by measuring the tricuspid regurgitation (TR) jet and adding this to right atrial pressure. The presence of a TR jet suggests increased pulmonary vascular resistance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Holly L Hedrick, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42226=[""].join("\n");
var outline_f41_15_42226=null;
var title_f41_15_42227="Betahistine: Patient drug information";
var content_f41_15_42227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Betahistine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17059?source=see_link\">",
"     see \"Betahistine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Betahistine;",
"     </li>",
"     <li>",
"      Novo-Betahistine;",
"     </li>",
"     <li>",
"      Serc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dizziness having to do with M&egrave;ni&egrave;re's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to betahistine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Pheochromocytoma or ulcer disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throwing up blood or throw up that looks like coffee grounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11995 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2959C7380A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42227=[""].join("\n");
var outline_f41_15_42227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140528\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014677\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014676\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014681\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014682\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014684\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014679\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014680\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014685\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014686\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17059?source=related_link\">",
"      Betahistine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_15_42228="Transverse incisions of the abdominal wall";
var content_f41_15_42228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Transverse incisions of the abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42228=[""].join("\n");
var outline_f41_15_42228=null;
var title_f41_15_42229="Atracurium: Pediatric drug information";
var content_f41_15_42229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atracurium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"    see \"Atracurium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/59/34739?source=see_link\">",
"    see \"Atracurium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atracurium Besylate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neuromuscular Blocker Agent, Nondepolarizing",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Paralytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11441966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Paralysis/skeletal muscle relaxation:",
"     </b>",
"     I.V.: 0.25-0.4 mg/kg initially followed by maintenance doses of 0.25 mg/kg as needed to maintain neuromuscular blockade",
"     <b>",
"      or",
"     </b>",
"     a continuous I.V. infusion 0.4 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Clarkson, 2001; Kalli, 1988);",
"     <b>",
"      Note:",
"     </b>",
"     Higher intermittent doses (eg, 0.5 mg/kg) have been associated with toxicity and fatal outcomes in premature neonates (Clarkson, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"      see \"Atracurium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Paralysis/skeletal muscle relaxation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &le;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.3-0.4 mg/kg initially followed by maintenance doses of 0.3-0.4 mg/kg as needed to maintain neuromuscular blockade",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: 0.6-1.2 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 10-20",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years to Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.4-0.5 mg/kg then 0.08-0.1 mg/kg 20-45 minutes after initial dose to maintain neuromuscular block; repeat dose at 15- to 25-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial: 0.54-0.6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 9-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute at initial signs of recovery from bolus dose; block is usually maintained by a rate of 0.3-0.54 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 5-9",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute (range: 0.1-0.9 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 2-15",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic or renal impairment:",
"     </b>",
"     Not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with enflurane or isoflurane:",
"     </b>",
"     Reduce dosage by 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with induced hypothermia (cardio-bypass surgery):",
"     </b>",
"     Reduce dosage by 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as besylate: 10 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as besylate [preservative free]: 10 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: May be administered without further dilution by rapid I.V. injection; for continuous I.V. infusions, dilute to a maximum concentration of 0.5 mg/mL (more concentrated solutions have reduced stability, ie, &lt;24 hours at room temperature); not for I.M. injection due to tissue irritation",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F137889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR;",
"     <b>",
"      variable (consult detailed reference):",
"     </b>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, amiodarone, cefazolin, cefuroxime, cimetidine, dobutamine, dopamine, epinephrine, esmolol, etomidate, fenoldopam, fentanyl, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, isoproterenol, lorazepam, midazolam, milrinone, morphine, nitroglycerin, nitroprusside, ranitidine, sodium nitroprusside, sulfamethoxazole/trimethoprim, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, propofol, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, fentanyl, midazolam, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from freezing; use vials within 14 days upon removal from the refrigerator to room temperature of 25&deg;C (77&deg;F). Unstable in alkaline solutions; compatible with D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, and NS; dilutions of 0.2 mg/mL or 0.5 mg/mL are stable for up to 24 hours at room temperature or under refrigeration; do not dilute in LR.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in ages &ge;1 month and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2973355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on",
"       <b>",
"        high alert",
"       </b>",
"       (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild, rare, and generally suggestive of histamine release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Bronchial secretions, erythema, hives, itching, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute quadriplegic myopathy syndrome (prolonged use), allergic reaction, bradycardia, bronchospasm, dyspnea, hypotension, injection site reaction, laryngospasm, myositis ossificans (prolonged use), seizure, tachycardia, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Causes of prolonged neuromuscular blockade:",
"     </b>",
"     Accumulation of active metabolites; cumulative drug effect, metabolism/excretion decreased (hepatic and/or renal impairment); electrolyte imbalance (hypokalemia, hypocalcemia, hypermagnesemia, hypernatremia); excessive drug administration; hypothermia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atracurium besylate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14197544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Certain clinical conditions may result in potentiation or antagonism of neuromuscular blockade, see table. Increased sensitivity in patients with myasthenia gravis, Eaton-Lambert syndrome; resistance to neuromuscular blockade in burn patients (&gt;30% of body) for period of 5-70 days postinjury; resistance in patients with muscle trauma, denervation, immobilization, infection, and prolonged treatment with atracurium. When used in conjunction with anesthetics, bradycardia may be more common with atracurium than with other neuromuscular blocking agents; it has no clinically significant effects on heart rate to counteract the bradycardia produced by anesthetics.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Clinical Conditions Affecting Neuromuscular Blockade",
"     </caption>",
"     <col align=\"left\" width=\"240\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Potentiation",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Antagonism",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Acidosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Acute intermittent porphyria",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Electrolyte abnormalities",
"        </p>",
"        <p style=\"text-indent:2em;\">",
"         Hypermagnesemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hyponatremia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypocalcemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypokalemia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hepatic failure",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Neuromuscular diseases",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Renal failure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Alkalosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Demyelinating lesions",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Diabetes mellitus",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hypercalcemia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Peripheral neuropathies",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ventilation must be supported during neuromuscular blockade; atracurium should only be administered by individuals who are experienced in the maintenance of an adequate airway and respiratory support. Atracurium does not alter consciousness; use in conjunction with adequate sedation or anesthesia. Severe allergic reactions have been reported with neuromuscular-blocking agents including atracurium; cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions. Reduce initial dosage and inject slowly (over 1-2 minutes) in patients in whom substantial histamine release would be potentially hazardous (eg, patients with clinically important cardiovascular disease); maintenance of an adequate airway and respiratory support is critical.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some formulations may contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of atracurium products containing benzyl alcohol in neonates; use preservative free product;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; avoid use of preservative-containing formulation in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13273269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Small amounts of atracurium have been shown to cross the placenta when given to women during cesarean section.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Muscle twitch response to peripheral nerve stimulation, heart rate, blood pressure, assisted ventilation status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Recovery begins in 20-35 minutes when anesthesia is balanced",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0.21 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Some metabolites are active; undergoes rapid nonenzymatic degradation (Hofmann elimination) in the bloodstream; additional metabolism occurs via ester hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 17 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 16 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 7.9 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 6.8 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 5.3 mL/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuromuscular blockade may be reversed with neostigmine; atropine or glycopyrrolate should be available to treat excessive cholinergic effects from neostigmine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Clarkson A, Choonara I, and Martin P, \"Suspected Toxicity of Atracurium in the Neonate,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2001, 11(5):631-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/15/42229/abstract-text/11696136/pubmed\" id=\"11696136\" target=\"_blank\">",
"        11696136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalli I and Meretoja OA, \"Infusion of Atracurium in Neonates, Infants and Children. A Study of Dose Requirements,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1988, 60(6):651-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/15/42229/abstract-text/3377949/pubmed\" id=\"3377949\" target=\"_blank\">",
"        3377949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(7):1358-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/15/42229/abstract-text/10446832 /pubmed\" id=\"10446832 \" target=\"_blank\">",
"        10446832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12862 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42229=[""].join("\n");
var outline_f41_15_42229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056635\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441966\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056629\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137843\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137829\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056638\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137889\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056632\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056637\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973355\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137888\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056642\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14197544\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056627\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298793\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137837\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137839\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056634\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056626\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056640\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056641\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056643\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12862\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12862|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=related_link\">",
"      Atracurium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/59/34739?source=related_link\">",
"      Atracurium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_15_42230="Clinical manifestations and diagnosis of carpal tunnel syndrome";
var content_f41_15_42230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of carpal tunnel syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42230/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42230/contributors\">",
"     Milind J Kothari, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42230/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42230/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/15/42230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (CTS) refers to the complex of symptoms and signs brought on by compression of the median nerve as it travels through the carpal tunnel. Patients commonly experience pain and paresthesia, and less commonly weakness, in the median nerve distribution. CTS is the most frequent compressive focal mononeuropathy seen in clinical practice.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and diagnosis of CTS. Other aspects of CTS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23911?source=see_link\">",
"     \"Etiology of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44008?source=see_link\">",
"     \"Treatment of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of classic CTS is pain or paresthesia (numbness and tingling) in a distribution that includes the median nerve territory, with involvement of the first three digits and the radial half of the fourth digit (",
"    <a class=\"graphic graphic_figure graphicRef70720 \" href=\"mobipreview.htm?37/44/38593\">",
"     figure 1",
"    </a>",
"    ). The symptoms of CTS are typically worse at night and often awaken patients from sleep. Some patients react to these symptoms by shaking or wringing their hands or by placing them under warm running water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the sensory symptoms of CTS are usually limited to the median-innervated fingers, there is a wide range of variability. The pain and paresthesia may be localized to the wrist or involve the entire hand. It is not uncommon for sensory symptoms to radiate proximally into the forearm, and less frequently to radiate above the elbow to the shoulder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CTS symptoms are often provoked by activities that involve flexing or extending the wrist or raising the arms, such as driving, reading, typing, and holding a telephone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral CTS is common at first presentation, affecting up to 65 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/3\">",
"     3",
"    </a>",
"    ]. In some cases, involvement is subclinical on one side and symptomatic on the other.",
"   </p>",
"   <p>",
"    The clinical course of CTS may follow an alternating pattern with periods of remission and exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/4\">",
"     4",
"    </a>",
"    ]. In some cases, there is progression from intermittent to persistent sensory complaints in the hand as CTS worsens, and later to the development of motor symptoms in the hand.",
"   </p>",
"   <p>",
"    In more severe cases of CTS, motor involvement leads to complaints of weakness or clumsiness when using the hands, such as difficulty holding objects, turning keys or doorknobs, buttoning clothing, or opening jar lids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinical signs may include weakness of thumb abduction and opposition, and atrophy of the thenar eminence.",
"   </p>",
"   <p>",
"    Fixed sensory loss is usually a late finding characterized by a distinctive clinical pattern that involves the median-innervated fingers and spares the thenar eminence. This pattern occurs because the palmar sensory cutaneous nerve arises proximal to the wrist and passes over, rather than through, the carpal tunnel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23911?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology of carpal tunnel syndrome\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTS is a clinical diagnosis. The diagnosis is suspected when the characteristic symptoms and signs are present. The most important of these are nocturnal pain or paresthesia in the distribution of the median nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The likelihood of the diagnosis is thought to correlate with the number of standard symptoms and provocative factors listed as criteria for the diagnosis of CTS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dull, aching discomfort in the hand, forearm, or upper arm",
"     </li>",
"     <li>",
"      Paresthesia in the hand",
"     </li>",
"     <li>",
"      Weakness or clumsiness of the hand",
"     </li>",
"     <li>",
"      Occurrence of any of these symptoms in the median distribution",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provocative factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sleep",
"     </li>",
"     <li>",
"      Sustained hand or arm positions",
"     </li>",
"     <li>",
"      Repetitive actions of the hand or wrist",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitigating factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Changes in hand posture",
"     </li>",
"     <li>",
"      Shaking the hand",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electrodiagnostic testing can be helpful to confirm or exclude CTS when the clinical diagnosis is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/5\">",
"     5",
"    </a>",
"    ]. It is also useful to gauge severity of nerve compression and to aid in decisions regarding surgical intervention. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Electrodiagnostic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The combination of characteristic symptoms and signs and confirmatory electrodiagnostic testing appears to be most accurate for the diagnosis of CTS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Objective sensory and motor deficits corresponding to the median nerve-innervated regions of the hand may be present, but their absence does not rule out the diagnosis of CTS.",
"   </p>",
"   <p>",
"    Sensation should be tested in all regions of the hand, forearm, and upper arm (",
"    <a class=\"graphic graphic_figure graphicRef61147 \" href=\"mobipreview.htm?40/17/41239\">",
"     figure 2",
"    </a>",
"    ). As mentioned above, sensory deficits usually occur late in the course of CTS; they involve the median-innervated fingers but spare the thenar eminence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/2\">",
"     2",
"    </a>",
"    ]. This is a critical finding, as sensory loss over the thenar eminence suggests a median nerve lesion proximal to the carpal tunnel.",
"   </p>",
"   <p>",
"    Objective weakness can occur in advanced CTS and is limited to muscles of the thenar eminence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/2\">",
"     2",
"    </a>",
"    ]. This manifests principally as weakness of thumb abduction and thumb opposition. Atrophy of the thenar eminence may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Provocative maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocative maneuvers for CTS include the Phalen, Tinel, manual carpal compression, and hand elevation tests. These can be helpful when interpreted in the proper clinical context. However, the sensitivity and specificity of these provocative tests is moderate at best [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the Phalen maneuver, the patient fully flexes the palms at the wrist with the elbow in full extension to provide extra pressure on the median nerve. Alternatively, the backs of the hands are placed against each other to provide hyperflexion of the wrist (",
"      <a class=\"graphic graphic_picture graphicRef68440 \" href=\"mobipreview.htm?24/53/25424\">",
"       picture 1",
"      </a>",
"      ), and the elbows remain flexed. A positive Phalen sign is defined as pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresthesia in the median-innervated fingers with one minute of wrist flexion. Meta-analyses have shown an average sensitivity of 68 percent and specificity of 73 percent for a positive Phalen's test [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/9\">",
"       9",
"      </a>",
"      ]. One prospective study found that Phalen's test correlated with CTS severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Tinel test (",
"      <a class=\"graphic graphic_picture graphicRef58010 \" href=\"mobipreview.htm?31/20/32064\">",
"       picture 2",
"      </a>",
"      ) involves firm percussion performed over the course of the median nerve just proximal to or on top of the carpal tunnel. A positive Tinel test is defined as pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresthesia of the median-innervated fingers that occurs with percussion over the median nerve. A positive Tinel sign may be less sensitive (50 percent) than the Phalen sign, but has similar specificity (77 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The manual carpal compression test is performed by applying pressure over the transverse carpal ligament, and it is deemed positive if paresthesia occur within 30 seconds of applying pressure. The average sensitivity and specificity of the manual carpal compression test is 64 and 83 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The hand elevation test involves raising the hands above head for one minute [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/11\">",
"       11",
"      </a>",
"      ]. The test is positive if it reproduces the symptoms of CTS. The sensitivity and specificity appear to be similar to or slightly better than those reported for Tinel and Phalen maneuvers, but few reports have compared these tests directly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve conduction studies (NCS) and electromyography (EMG) are a standard part of the evaluation for CTS. They are useful to support the diagnosis of CTS, to assess severity, and to rule out other abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/13\">",
"     13",
"    </a>",
"    ]. The diagnosis is primarily dependent on results from the NCS. The main utility of EMG is to exclude other conditions such as polyneuropathy, plexopathy, and radiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrodiagnostic studies are essential if surgical treatment for CTS is being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nerve conduction studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrodiagnosis of CTS rests upon the demonstration of impaired median nerve conduction across the carpal tunnel in the context of normal conduction elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. Nerve compression results in damage to the myelin sheath and manifests as delayed distal latencies and slowed conduction velocities. With sustained or more severe compression, axon loss may also occur, resulting in a reduction of the median nerve compound motor or sensory action potential amplitude.",
"   </p>",
"   <p>",
"    The NCS evaluation for CTS involves measurement of conduction velocity across the carpal tunnel, as well as determination of the amplitude of sensory and motor responses. Mild CTS may not produce any nerve conduction abnormalities. With increased compression of the median nerve, focal demyelination can occur. This may result in local conduction block",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slowing of motor and sensory conduction across the wrist. With even greater compression, the axons of the median nerve themselves can be damaged, resulting in reduced amplitudes. Sensory fibers seem to be more sensitive to compression than motor fibers. As a result, sensory fibers typically demonstrate changes on nerve conduction studies earlier than do motor fibers.",
"   </p>",
"   <p>",
"    Sensory conduction studies may involve branches that innervate any of the first four digits, depending on clinical symptoms. Motor conduction studies most often record from the abductor pollicis brevis muscle, although other muscles can provide added information. Results obtained are compared to age-dependent normal values, as well as to other nerves of the same hand or the contralateral hand. In particular, the ulnar nerve and sometimes the radial nerve are also evaluated to ensure that any abnormalities seen in the median nerve are specific to that nerve and not part of a more widespread disorder, such as a peripheral neuropathy.",
"   </p>",
"   <p>",
"    Routine NCS for the diagnosis of CTS typically include the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median motor conduction study recording from the abductor pollicis brevis while stimulating at the wrist and elbow",
"     </li>",
"     <li>",
"      Ulnar motor conduction study recording from the abductor digiti minimi while stimulating at the wrist and at the elbow above and below the ulnar groove",
"     </li>",
"     <li>",
"      Median and ulnar F responses",
"     </li>",
"     <li>",
"      Median sensory response recording from digit two or three while stimulating the wrist",
"     </li>",
"     <li>",
"      Ulnar sensory response recording from digit five while stimulating the wrist",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional comparison studies should be used for patients who have normal routine NCS in the setting of clinical findings suggestive of CTS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palmar mixed-nerve study, comparing palm-to-wrist peak latencies of median and ulnar nerves, each recorded 8 cm from the stimulating electrodes",
"     </li>",
"     <li>",
"      Second lumbrical (median) versus interossei (ulnar) distal motor latencies",
"     </li>",
"     <li>",
"      Digit four sensory latencies stimulating the median and ulnar nerves at the wrist individually at identical distances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These methods compare the conductions of median fibers directly with ulnar fibers traveling in the same region. In a 2002 systematic review of prospective studies, the sensitivity of various NCS for CTS ranged from 56 to 85 percent, and the specificity ranged from 94 to 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/13\">",
"     13",
"    </a>",
"    ]. In a later study of 99 patients meeting clinical criteria for CTS without confounding neurologic disorders, NCS (including median and ulnar palmar mixed-nerve studies) were normal in 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anomalous innervations are not uncommonly seen during electrodiagnostic testing. The one most frequently encountered in the arm is the Martin-Gruber anastomosis, which has a prevalence of 15 to 32 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. With this median-to-ulnar anastomosis, a subgroup of motor fibers split from the median nerve in the forearm and anastomose with the ulnar nerve as it travels through the forearm into the hand. The median-to-ulnar motor fibers that make up this anastomosis innervate the intrinsic muscles of the hand.",
"   </p>",
"   <p>",
"    The Martin-Gruber anastomosis is most often identified during ulnar nerve testing. During median nerve motor studies, one may see a pattern where the amplitude of the compound muscle action potential is higher with stimulation at the proximal elbow site than with stimulation at the wrist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/18\">",
"     18",
"    </a>",
"    ]. In the setting of median nerve entrapment at the wrist (CTS), a surprisingly fast median nerve conduction velocity in the forearm can be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These electrodiagnostic findings are intuitive if one keeps in mind that not all median motor fibers are taking their normal route through the carpal tunnel. Instead, they are bypassing the site of entrapment by taking this circuitous route with the ulnar nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the electrodiagnosis of CTS depends mainly upon the demonstration of impaired median nerve conduction across the carpal tunnel. EMG is most useful to exclude other conditions, such as polyneuropathy, plexopathy, and radiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EMG portion of the electrophysiologic examination looks for evidence of pathologic changes in the muscles innervated by the median nerve, typically assessing the abductor pollicis brevis muscle. When secondary axonal loss is present, EMG may reveal either active denervation (eg, spontaneous activity such as fibrillation potentials, positive sharp waves, and fasciculation potentials) or chronic changes that indicate denervation with subsequent reinnervation (eg, changes in motor unit action potential amplitudes, durations, and recruitment)",
"   </p>",
"   <p>",
"    Such findings are supportive of the diagnosis of CTS in the context of normal findings in both nonmedian-innervated muscles and proximal median nerve-innervated muscles.",
"   </p>",
"   <p>",
"    One suggested protocol for EMG evaluation of CTS involves needle examination of the following muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abductor pollicis brevis",
"     </li>",
"     <li>",
"      Two or more C6-C7 innervated muscles (eg, pronator teres, triceps brachii, extensor digitorum communis) to look for evidence of cervical radiculopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional muscles are investigated if the abductor pollicis brevis is abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two or more proximal median-innervated muscles (eg, flexor carpi radialis, pronator teres, flexor pollicis longus) to rule out a proximal median neuropathy",
"     </li>",
"     <li>",
"      Two or more lower trunk C8-T1 nonmedian-innervated muscles (eg, first dorsal interosseous, extensor indicis proprius) to rule out brachial plexopathy, polyneuropathy, and C8 to T1 radiculopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are not routinely employed in the evaluation for possible CTS. Several studies using ultrasonography have shown that patients with CTS have significantly increased cross-sectional area of the median nerve compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. However, the optimal cross-sectional area cutoff for the diagnosis, as well as the sensitivity and specificity of this technique, has varied in these reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In a systematic review of the literature published through May 2011, the four highest-quality studies used cutoffs of 8.5 to 10 mm",
"    <sup>",
"     2",
"    </sup>",
"    for the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/27\">",
"     27",
"    </a>",
"    ]. The sensitivities ranged from 65 to 97 percent and the specificities ranged from 73 to 98 percent.",
"   </p>",
"   <p>",
"    MRI can detect abnormalities of the median nerve, flexor tendons, vascular structures, and transverse carpal ligament in the region of the carpal tunnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42230/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, the diagnostic utility of MRI for CTS remains uncertain. Thus, MRI is rarely ordered and is reserved for unusual cases to rule out a mass lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/49/18194?source=see_link\">",
"       \"Patient information: Carpal tunnel syndrome (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=see_link\">",
"       \"Patient information: Hand pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmark of classic CTS is pain or paresthesia (numbness and tingling) in a distribution that includes the median nerve territory, with involvement of the first three digits and the radial half of the fourth digit (",
"      <a class=\"graphic graphic_figure graphicRef70720 \" href=\"mobipreview.htm?37/44/38593\">",
"       figure 1",
"      </a>",
"      ). The symptoms are typically worse at night and characteristically awaken affected patients from sleep. Bilateral CTS is common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of CTS have a wide range of variability (",
"      <a class=\"graphic graphic_figure graphicRef61147 \" href=\"mobipreview.htm?40/17/41239\">",
"       figure 2",
"      </a>",
"      ). The pain and paresthesia may be localized to the wrist, involve the entire hand, or radiate proximally to as high as the shoulder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CTS symptoms are often provoked by activities that involve flexing or extending the wrist or raising the arms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In more severe CTS, motor involvement leads to complaints of weakness or clumsiness when using the hands. Clinical signs may include weakness of thumb abduction and opposition, and atrophy of the thenar eminence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CTS is a clinical diagnosis that is suspected when the characteristic symptoms and signs are present. The most important of these are nocturnal pain or paresthesia in the distribution of the median nerve. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provocative maneuvers for CTS include the Phalen, Tinel, manual carpal compression, and hand elevation tests. These can be helpful when interpreted in the proper clinical context. However, the sensitivity and specificity of these tests is moderate at best. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Provocative maneuvers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nerve conduction studies (NCS) and electromyography (EMG) are useful to support the diagnosis of CTS and to rule out other abnormalities. The electrodiagnosis of CTS rests upon the demonstration of impaired median nerve conduction across the carpal tunnel in the context of normal conduction elsewhere. EMG is used to exclude other conditions such as polyneuropathy, plexopathy, and radiculopathy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Electrodiagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Dr. Kevin Scott, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Preston, DC, Shapiro, BE. Median neuropathy. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, Butterworth-Heinemann, Boston 1998. p.231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/2\">",
"      Bland JD. Carpal tunnel syndrome. BMJ 2007; 335:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/3\">",
"      Bland JD, Rudolfer SM. Clinical surveillance of carpal tunnel syndrome in two areas of the United Kingdom, 1991-2001. J Neurol Neurosurg Psychiatry 2003; 74:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/4\">",
"      Muller M, Tsui D, Schnurr R, et al. Effectiveness of hand therapy interventions in primary management of carpal tunnel syndrome: a systematic review. J Hand Ther 2004; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/5\">",
"      Bland JD. Carpal tunnel syndrome. Curr Opin Neurol 2005; 18:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/6\">",
"      Rempel D, Evanoff B, Amadio PC, et al. Consensus criteria for the classification of carpal tunnel syndrome in epidemiologic studies. Am J Public Health 1998; 88:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/7\">",
"      Katz JN, Larson MG, Sabra A, et al. The carpal tunnel syndrome: diagnostic utility of the history and physical examination findings. Ann Intern Med 1990; 112:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/8\">",
"      D'Arcy CA, McGee S. The rational clinical examination. Does this patient have carpal tunnel syndrome? JAMA 2000; 283:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/9\">",
"      MacDermid JC, Wessel J. Clinical diagnosis of carpal tunnel syndrome: a systematic review. J Hand Ther 2004; 17:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/10\">",
"      Priganc VW, Henry SM. The relationship among five common carpal tunnel syndrome tests and the severity of carpal tunnel syndrome. J Hand Ther 2003; 16:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/11\">",
"      Ahn DS. Hand elevation: a new test for carpal tunnel syndrome. Ann Plast Surg 2001; 46:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/12\">",
"      Practice parameter for carpal tunnel syndrome (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1993; 43:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/13\">",
"      Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: Electrodiagnostic studies in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2002; 58:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/14\">",
"      Jillapalli D, Shefner JM. Electrodiagnosis in common mononeuropathies and plexopathies. Semin Neurol 2005; 25:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/15\">",
"      Witt JC, Hentz JG, Stevens JC. Carpal tunnel syndrome with normal nerve conduction studies. Muscle Nerve 2004; 29:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/16\">",
"      Amoiridis G. Median--ulnar nerve communications and anomalous innervation of the intrinsic hand muscles: an electrophysiological study. Muscle Nerve 1992; 15:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/17\">",
"      Rodriguez-Niedenf&uuml;hr M, Vazquez T, Parkin I, et al. Martin-Gruber anastomosis revisited. Clin Anat 2002; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     Preston, DC, Shapiro, BE. Anomalous innervations. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, Butterworth-Heinemann, Boston 1998. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/19\">",
"      Rubin DI, Dimberg EL. Martin-Gruber anastomosis and carpal tunnel syndrome: [corrected] morphologic clues to identification. Muscle Nerve 2010; 42:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/20\">",
"      Ashraf AR, Jali R, Moghtaderi AR, Yazdani AH. The diagnostic value of ultrasonography in patients with electrophysiologicaly confirmed carpal tunnel syndrome. Electromyogr Clin Neurophysiol 2009; 49:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/21\">",
"      Yesildag A, Kutluhan S, Sengul N, et al. The role of ultrasonographic measurements of the median nerve in the diagnosis of carpal tunnel syndrome. Clin Radiol 2004; 59:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/22\">",
"      Visser LH, Smidt MH, Lee ML. High-resolution sonography versus EMG in the diagnosis of carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 2008; 79:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/23\">",
"      Moran L, Perez M, Esteban A, et al. Sonographic measurement of cross-sectional area of the median nerve in the diagnosis of carpal tunnel syndrome: correlation with nerve conduction studies. J Clin Ultrasound 2009; 37:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/24\">",
"      Wiesler ER, Chloros GD, Cartwright MS, et al. The use of diagnostic ultrasound in carpal tunnel syndrome. J Hand Surg Am 2006; 31:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/25\">",
"      Mhoon JT, Juel VC, Hobson-Webb LD. Median nerve ultrasound as a screening tool in carpal tunnel syndrome: correlation of cross-sectional area measures with electrodiagnostic abnormality. Muscle Nerve 2012; 46:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/26\">",
"      Descatha A, Huard L, Aubert F, et al. Meta-analysis on the performance of sonography for the diagnosis of carpal tunnel syndrome. Semin Arthritis Rheum 2012; 41:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/27\">",
"      Cartwright MS, Hobson-Webb LD, Boon AJ, et al. Evidence-based guideline: neuromuscular ultrasound for the diagnosis of carpal tunnel syndrome. Muscle Nerve 2012; 46:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/28\">",
"      Jarvik JG, Yuen E, Haynor DR, et al. MR nerve imaging in a prospective cohort of patients with suspected carpal tunnel syndrome. Neurology 2002; 58:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42230/abstract/29\">",
"      Uchiyama S, Itsubo T, Yasutomi T, et al. Quantitative MRI of the wrist and nerve conduction studies in patients with idiopathic carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 2005; 76:1103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5288 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42230=[""].join("\n");
var outline_f41_15_42230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Provocative maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5288|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/44/38593\" title=\"figure 1\">",
"      Median sensory territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/17/41239\" title=\"figure 2\">",
"      Hand symptom diagram CTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5288|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/53/25424\" title=\"picture 1\">",
"      Phalen test carpal tunnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/20/32064\" title=\"picture 2\">",
"      Tinel test carpal tunnel",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23911?source=related_link\">",
"      Etiology of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/49/18194?source=related_link\">",
"      Patient information: Carpal tunnel syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_15_42231="Large septated fetal cystic hygroma with hydrops";
var content_f41_15_42231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53158%7EOBGYN%2F64913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53158%7EOBGYN%2F64913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of the fetal head of an early second trimester fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surrounding the fetal cranium is a large septated cystic hygroma. The fluid extends beyond the nuchal region and diffusely involves the skin throughout the fetus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of the fetal head of an early second trimester fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior and lateral to the cranium is a large septated cystic hygroma. Very little amniotic fluid is present in this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42231=[""].join("\n");
var outline_f41_15_42231=null;
var title_f41_15_42232="Cardiotoxicity of trastuzumab";
var content_f41_15_42232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiotoxicity of trastuzumab",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     Edith A Perez, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42232/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/15/42232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    is a monoclonal antibody that targets the human epidermal growth factor receptor-2 (HER2, also ErbB2). For the 15 to 20 percent of patients with breast cancer whose tumors overexpress HER2, trastuzumab therapy is important in the treatment of early and advanced disease. Its use, however, results in a small to modest risk for cardiotoxicity, which is typically manifested by an asymptomatic decrease in left ventricular ejection fraction and less often by clinical heart failure.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    -related cardiotoxicity, including its incidence, risk factors, recommendations for cardiac monitoring, and dosing of trastuzumab in patients who develop cardiotoxicity will be presented here. The cardiotoxicity of other antineoplastic drugs, including anthracyclines, taxanes, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    , management of heart failure, and clinical use of trastuzumab are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=see_link\">",
"       \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"       \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39982900\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    -related cardiotoxicity is most often manifested by an asymptomatic decrease in left ventricular ejection fraction (LVEF) and less often by clinical heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In contrast to cardiotoxicity from anthracyclines, trastuzumab-related cardiotoxicity does not appear to be related to cumulative dose. It is often reversible with treatment discontinuation, and rechallenge is often tolerated after recovery. In addition, cardiac biopsy specimens after trastuzumab exposure do not show significant myocyte destruction characteristic of anthracycline-induced dysfunction.",
"   </p>",
"   <p>",
"    These differences have led to the terms \"Type I\" and \"Type II\" chemotherapy-related cardiac dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/4\">",
"     4",
"    </a>",
"    ]. Type I, associated with the anthracyclines, results, at least to some degree, in myocyte destruction and clinical heart failure. Type II, a phenomenon that is not unique to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , is more often associated with a loss of contractility (presumably a form of stunning or hibernation) that is less likely to be associated with myocyte death or clinical heart failure and is more likely to be reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39983118\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity varies according to patient-related factors such as previous chemotherapy, preexisting heart disease, and age. The following data are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      in metastatic breast cancer, the incidence of cardiac toxicity was variable, with rates for patients who received trastuzumab alone, trastuzumab and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , and trastuzumab plus an anthracycline and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      of 3 to 7, 13, and 27 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. In contrast, of the patients not treated with trastuzumab, cardiotoxicity was noted in 8 percent of patients treated with an anthracycline plus cyclophosphamide and in 1 percent treated with paclitaxel. Of note, most of the patients not treated concurrently with an anthracycline and trastuzumab had received prior anthracycline therapy.",
"     </li>",
"     <li>",
"      A more modest incidence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -associated cardiotoxicity was seen in the major trials of adjuvant trastuzumab for HER2-positive breast cancer, which required more stringent and consistent cardiac monitoring and excluded patients with abnormal cardiac function. These trials, which included 10,000 patients randomly assigned to treatment with trastuzumab, were the Herceptin Adjuvant (HERA) trial, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial, the North Central Cancer Treatment Group (NCCTG) N9831 trial, the Breast Cancer International Research Group (BCIRG) 006, and the Finland Herceptin (FinHER) trial (",
"      <a class=\"graphic graphic_table graphicRef70022 \" href=\"mobipreview.htm?18/18/18733\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/7-16\">",
"       7-16",
"      </a>",
"      ]. Overall, the incidence of severe heart failure (New York Heart Association class III or IV, (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )) was 0 to 3.9 percent among trastuzumab-treated patients versus 0 to 1.3 percent in patients not receiving trastuzumab. In trials administering trastuzumab for more than six months, a decline in ejection fraction of 10 to 15 percent or more was seen in 3 to 34 percent of patients treated with trastuzumab, which was mostly reversible, as compared to 2 to 17 percent in patients not receiving trastuzumab.",
"      <br/>",
"      <br/>",
"      Among the individual trials, the incidence of severe cardiotoxicity (grade III or IV heart failure or death from cardiac causes) was significantly lower in patients who did not receive an anthracycline (0.4 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and trastuzumab treated patients in BCIRG 006) as compared to those patients treated with an anthracycline (2 to 4 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      followed by a taxane and trastuzumab) (",
"      <a class=\"graphic graphic_table graphicRef73709 \" href=\"mobipreview.htm?13/30/13805\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/10,14\">",
"       10,14",
"      </a>",
"      ]. Factors identified in these trials as associated with a greater risk of cardiotoxicity, and the contribution of anthracyclines to the risk of trastuzumab-related cardiotoxicity are also discussed below. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H95247583\">",
"       'Acceptable concurrent treatment'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      A 2012 meta-analysis of these five trials plus three others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/17-19\">",
"       17-19",
"      </a>",
"      ] enrolling 11,991 women with HER2-positive early breast cancer confirmed a significantly increased risk for severe heart failure (2.5 versus 0.4 percent, relative risk [RR] 5.11, 90% CI 3.00-8.72) and reduction in left ventricular ejection fraction (RR 1.83, 90% CI 1.36-2.47) in patients treated with trastuzumab versus non-trastuzumab-based adjuvant or neoadjuvant chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/20\">",
"       20",
"      </a>",
"      ]. There was no difference in the cardiotoxicity profile in trials with concurrent as compared to sequential administration of chemotherapy and trastuzumab. A shorter treatment period (six months or less) did not appear to be associated with an increase in the risk of heart failure (RR 0.5, 95% CI 0.07-3.74), although the analysis was based on only one trial (FinHER).",
"     </li>",
"     <li>",
"      The risk of cardiotoxicity may be greater in the general population not treated on clinical studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The patients in the adjuvant studies were relatively young and none had baseline cardiac disease, which was considered an exclusion factor for all of the trials. This was shown in shown in a single population-based study of 12,500 women diagnosed with invasive locoregional breast cancer over an eight-year period at eight integrated health systems who received no chemotherapy (n=5807), anthracycline-based chemotherapy (n=3697),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -based therapy without an anthracycline (n=112), anthracycline plus trastuzumab (n=442), or other chemotherapy (n=2442) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There was a high incidence of heart",
"      <span class=\"nowrap\">",
"       failure/cardiomyopathy",
"      </span>",
"      among patients treated with trastuzumab plus an anthracycline (cumulative incidence 20.1 percent at five years) despite the finding that these patients were more likely to be younger with fewer comorbidities. In contrast, the rate of heart",
"      <span class=\"nowrap\">",
"       failure/cardiomyopathy",
"      </span>",
"      was much lower among women who received non-trastuzumab-containing chemotherapy, and similar among those who received an anthracycline without trastuzumab and those treated with other non-anthracycline chemotherapy (cumulative incidence at five years 4.3 and 4.5 percent, respectively).",
"      <br/>",
"      <br/>",
"      The risk of heart",
"      <span class=\"nowrap\">",
"       failure/cardiomyopathy",
"      </span>",
"      among women treated with combined anthracycline plus trastuzumab relative to those who did not receive any chemotherapy was unexpectedly higher than clinical trial estimates, particularly among women less than age 55 (HR 16.36, 95% CI 6.59-40.65), cumulative incidence to year 5 was 7.5 percent (95% CI 0-85.9 percent). This finding was unchanged after excluding women with more comorbidities. While the reasons for these findings are not clear, it may be at least partially due to detection bias, as young women receiving these agents are much more likely to be monitored for cardiac failure than are young women who received no chemotherapy.",
"      <br/>",
"      <br/>",
"      These data must be interpreted with caution. The details of the cases (in particular whether the diagnosis of heart failure was based on a cardiology examination) and subsequent therapies were not rigorously documented, and there could be a significant misclassification of cases. In our own experience, the degree of cardiac problems in our patients is much less frequent than suggested by this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology underlying",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiac dysfunction is not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Because many patients who receive trastuzumab have previously received anthracyclines, it had been initially postulated that modification or exacerbation of anthracycline-related damage was responsible. However, endomyocardial biopsies from patients with trastuzumab-related cardiac dysfunction do not show typical anthracycline-related ultrastructural changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, trastuzumab-related cardiotoxicity may occur even in patients not exposed to anthracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/26\">",
"     26",
"    </a>",
"    ]. Further confounding the picture is that trastuzumab-related cardiotoxicity is not dependent on cumulative dose, may be largely reversible, and rechallenge with trastuzumab may be well-tolerated.",
"   </p>",
"   <p>",
"    Evidence from both in vivo and in vitro studies indicate the importance of the epidermal growth factor signalling system (HER2 or ErbB2) in the normal heart and suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    cardiotoxicity is directly related to HER2 blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In animal models, HER2 signaling is important for embryonic cardiac development and myocyte survival as well as protection from potential cardiotoxins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/28-30\">",
"       28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice with ventricular-restricted knockout of the HER2 gene spontaneously develop signs of a dilated cardiomyopathy, and their cardiomyocytes show enhanced susceptibility to anthracycline-induced cell death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/31-34\">",
"       31-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although the role of HER2 in the pathophysiology of heart failure is not well understood, serum HER2 levels are increased in patients with chronic heart failure, and levels correlate inversely with left ventricular function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism underlying the synergistic cardiotoxicity seen with anthracyclines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is unclear, but upregulation of HER2 expression by anthracyclines may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/37\">",
"     37",
"    </a>",
"    ]. Other mechanisms for trastuzumab-related cardiotoxicity may be operative since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    , another HER2-directed agent, is only rarely associated with clinically relevant cardiotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H45#H45\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Lapatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with a higher likelihood of developing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity include previous or concurrent anthracycline use and age greater than 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/5,8,21,38-40\">",
"     5,8,21,38-40",
"    </a>",
"    ]. In contrast, concurrent treatment with trastuzumab and adjuvant radiation therapy does not increase the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other risk factors identified by multivariate analysis are preexisting cardiac dysfunction (ie, decreased left ventricular ejection fraction), older age, high body mass index, and antihypertensive therapy, while diabetes, valvular heart disease, and coronary artery disease did not significantly increase risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/11,38,42\">",
"     11,38,42",
"    </a>",
"    ]. On the other hand, at least a very small dataset suggests that diabetes is a risk factor for cardiotoxicity among elderly women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . In a study of 45 elderly women receiving trastuzumab either in the adjuvant setting or for metastatic disease, the risk of cardiotoxicity was 33 versus 6 percent for patients with and without diabetes, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34826?source=see_link&amp;anchor=H33#H33\">",
"     \"Adjuvant systemic therapy for older women with early stage breast cancer\", section on 'Cardiotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40903?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of metastatic breast cancer in older women\", section on 'HER2-directed agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiac dysfunction is highest in those patients who receive concurrent anthracyclines (especially if the cumulative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    dose is &gt;300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    the risk is modestly elevated for trastuzumab after previous anthracycline, and is minimally if at all increased for trastuzumab and a taxane, for trastuzumab in combination with endocrine therapy, and for trastuzumab alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/5-14,23\">",
"     5-14,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cardiac risk score that includes age and baseline LVEF has been developed by investigators from the NSABP based upon data from NSABP B-31 trial to predict the absolute risk of heart failure in individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/42\">",
"     42",
"    </a>",
"    ]. However, independent validation of this model is needed before it can be considered for general use. (See",
"    <a class=\"local\" href=\"#H14457353\">",
"     'Reversibility and rechallenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14457353\">",
"    <span class=\"h1\">",
"     REVERSIBILITY AND RECHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    -related cardiotoxicity is largely reversible in the majority of cases, and treatment continuation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resumption of trastuzumab after resolution of cardiac abnormalities may be safe in some women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/2,5,25,39,44\">",
"     2,5,25,39,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III trial of chemotherapy with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      conducted in women with metastatic breast cancer, 33 patients continued trastuzumab for a median of 26 weeks despite developing a cardiac event (most often an asymptomatic decline in left ventricular ejection fraction [LVEF]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/5,45\">",
"       5,45",
"      </a>",
"      ]. The cardiac status of 28 patients (85 percent) improved or remained the same. Symptoms were reversible for 75 percent of those who received standard heart failure therapy.",
"     </li>",
"     <li>",
"      In a retrospective review of 49 patients who developed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -related cardiotoxicity, 79 percent of those who stopped trastuzumab after developing symptomatic heart failure recovered with appropriate therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/44\">",
"       44",
"      </a>",
"      ]. However, three patients did not recover, and one died of progressive heart failure. Treatment was reinitiated in 26 patients who interrupted trastuzumab for either an asymptomatic or symptomatic cardiac event, 16 (62 percent) of whom remained without evidence of subsequent cardiac toxicity. In patients with an asymptomatic reduction in LVEF, of whom 41 percent discontinued trastuzumab, LVEF recovered completely in 89 percent, with or without heart failure therapy. Even among the 10 patients who developed recurrent cardiac dysfunction after reintroduction, five were able to continue trastuzumab while maintaining a slightly reduced LVEF as the only sign of cardiotoxicity.",
"     </li>",
"     <li>",
"      Reversibility was addressed in a seven-year follow-up analysis of the NSABP B-31 adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      trial, in which patients with node-positive HER2-positive breast cancer were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without concurrent trastuzumab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/42\">",
"       42",
"      </a>",
"      ]. The cumulative risk of a cardiac event (defined as definite or probable cardiac death or heart failure manifested by dyspnea with normal activity or at rest and associated with a decline in LVEF if &gt;10 percentage points from baseline to a value &lt;55 percent, or a decrease of &gt;5 percent or a value below the lower limit of normal) to seven years was 4.0 percent in the trastuzumab arm versus 1.3 percent in the non-trastuzumab arm.",
"      <br/>",
"      <br/>",
"      Among the 37 evaluable patients who received trastuzumab and met criteria for a cardiac event, one died because of heart failure. Of the remaining 36 patients, 33 were without symptoms of cardiac disease when assessed &ge;6 months after their diagnosis of heart failure, although 21 continued to receive cardiac medications. LVEF measurements recovered to at least 50 percent in 21.",
"      <br/>",
"      <br/>",
"      Of the 50 patients who were symptomatic but did not meet criteria for a cardiac event, 49 were observed for at six months since onset of symptoms, and none reported symptoms of cardiac disease on last follow-up, although 12 continued to receive cardiac medication. Of the 114 evaluable patients with asymptomatic decline in LVEF during therapy who discontinued trastuzumab, 27 subsequently reported symptoms of possible cardiac disease. Of the remaining 87, LVEF was reported in 69 at least six months after discontinuation of trastuzumab, and only 15 still had an LVEF &lt;50 percent.",
"      <br/>",
"      <br/>",
"      The authors developed a cardiac risk score including age and baseline LVEF to predict the absolute risk of heart failure in individual patients. When cardiac risk scores were plotted against a modeled heart failure risk curve, it was estimated that a 45-year old woman with a baseline LVEF of 65 percent would have a 2.3 percent predicted risk of a cardiac event whereas a 65-year-old woman with a baseline LVEF of 55 percent would have a 13 percent predicted risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/46\">",
"       46",
"      </a>",
"      ]. However, validation of this risk prediction tool is needed before it can be considered for use in general practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14451472\">",
"    <span class=\"h1\">",
"     CLINICAL GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    therapy is planned for patients in the adjuvant or metastatic setting, the patient&rsquo;s risk for trastuzumab-related cardiotoxicity should be carefully assessed and weighed against the benefits of trastuzumab treatment. In the adjuvant setting, trastuzumab therapy is likely to be held or discontinued for asymptomatic cardiac dysfunction, and thus baseline and serial screening of left ventricular ejection fraction (LVEF) is appropriate. In the metastatic setting, the decision is more complex, given the clinical benefit provided by trastuzumab.",
"   </p>",
"   <p>",
"    Increased vigilance for signs and symptoms of cardiotoxicity is appropriate for higher risk patients. Without clinical trials specifically evaluating cardiac monitoring and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    dosing with cardiotoxicity, we generally follow the protocols used in the cooperative group clinical trials of trastuzumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14451831\">",
"    <span class=\"h2\">",
"     Baseline evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac function should be assessed prior to the institution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    therapy in both the adjuvant and metastatic settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/1,47\">",
"     1,47",
"    </a>",
"    ]. When treatment with trastuzumab follows use of an anthracycline, an assessment of left ventricular ejection fraction (LVEF) should be done after completion of the anthracycline and prior to initiation of trastuzumab.",
"   </p>",
"   <p>",
"    Patients with a normal baseline LVEF and no signs or symptoms of heart failure on physical examination may proceed with therapy. Patients with a modestly increased risk for cardiotoxicity include those with borderline LVEF (usually 40 to 50 percent), age &gt;50 years, and hypertension; they may proceed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , after weighing of the risks and benefits of trastuzumab therapy, but we and others recommend increased vigilance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/38,45\">",
"     38,45",
"    </a>",
"    ]. Trastuzumab therapy is generally safe in patients with coronary artery disease and valvular disease, but warrants careful monitoring.",
"   </p>",
"   <p>",
"    Noninvasive methods for LVEF estimation are discussed separately. Whichever method is selected for a baseline assessment should be continued for serial screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14452747\">",
"    <span class=\"h2\">",
"     Cardiac monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surveillance for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity is not defined. Several groups have proposed clinical guidelines, but none have been validated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/1,38,48\">",
"     1,38,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the adjuvant setting, we perform a baseline evaluation for cardiac function with a repeat study at six months. Others prefer more intensive serial monitoring of cardiac function at baseline, three, six, and nine months during treatment, and then at 12 and 18 months after the initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/47\">",
"     47",
"    </a>",
"    ]. Monitoring should be repeated during or following treatment as clinically indicated. Specific guidelines for routine cardiac monitoring in the metastatic setting have not been developed, and monitoring is based on investigator's discretion. Typically in patients treated for metastatic disease, LVEF is monitored at baseline and then infrequently in the absence of symptoms.",
"   </p>",
"   <p>",
"    Troponin I levels are elevated after anthracycline administration, predicting later cardiotoxicity, and may also have utility as a marker in establishing the diagnosis and prognosis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity. In a trial of 251 trastuzumab-treated patients who had troponin I levels measured before and after each trastuzumab cycle in addition to routine LVEF monitoring, troponin I identified patients who were more likely to develop trastuzumab-related cardiotoxicity and who were less likely to recover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Until these results are confirmed, however, troponin I levels should not be used to monitor patients on trastuzumab.",
"   </p>",
"   <p>",
"    In both the adjuvant and metastatic settings, clinical signs and symptoms, including increased heart rate or weight (&ge;2 kg in one week), edema, S3 gallop, or new dyspnea on exertion should prompt further evaluation and are in fact sufficient for a diagnosis of cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/1,3,38\">",
"     1,3,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95247366\">",
"    <span class=\"h2\">",
"     Trastuzumab dose adjustments for cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;We follow the dosing guidelines for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    as outlined in the clinical trials of adjuvant trastuzumab (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-31 trial and the North Central Cancer Treatment Group [NCCTG] N9831 trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/10\">",
"     10",
"    </a>",
"    ]. As discussed above, LVEF is infrequently monitored in the metastatic setting, and instead is reserved for patients with suspicious symptoms or physical findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the LVEF declines 16 or more percentage points from baseline or 10 to 15 percentage points from baseline to below the lower limit of normal,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      is withheld for four weeks, at which time the LVEF is reassessed.",
"     </li>",
"     <li>",
"      If the LVEF remains below these levels,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      should be discontinued.",
"     </li>",
"     <li>",
"      If the patient has symptomatic heart failure while receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , trastuzumab should be discontinued. Symptomatic (clinical) heart failure is defined by the presence of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms (dyspnea, orthopnea, pedal edema)",
"     </li>",
"     <li>",
"      Objective findings (elevated jugular venous pressure, sinus tachycardia, tachypnea, S3 gallop, crackles), and",
"     </li>",
"     <li>",
"      LVEF decline or chest radiograph findings of pulmonary edema or increased vascular markings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14451604\">",
"    <span class=\"h2\">",
"     Heart failure treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    -related cardiotoxicity usually responds to standard medical treatment for heart failure and discontinuation of trastuzumab in most, although not all, patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/1,6,8,44\">",
"     1,6,8,44",
"    </a>",
"    ]. Although treatment of trastuzumab-related cardiotoxicity has not been formally studied in clinical trials, standard medical therapy for heart failure, including beta blockers and angiotensin converting enzyme (ACE) inhibitors, should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Pharmacologic therapy of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95247583\">",
"    <span class=\"h1\">",
"     ACCEPTABLE CONCURRENT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiac dysfunction was significant when trastuzumab was administered concurrently with anthracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/6\">",
"     6",
"    </a>",
"    ]. However, on further analysis, the risk began to increase when the cumulative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    dose exceed 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and was quite low at cumulative doses below 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    There is accumulating evidence that concurrent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    may be safe when the cumulative doxorubicin dose is limited to 180",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/17,51-53\">",
"     17,51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Finland Herceptin (FinHER) trial, little cardiac toxicity (&lt;1 percent with symptomatic heart failure) was detected in those patients treated with adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      administered prior to an anthracycline (trastuzumab for nine weeks with three cycles of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      followed by additional adjuvant chemotherapy with three cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [FEC]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the NeOAdjuvant Herceptin (NOAH) trial, patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (for a total duration of one year) concurrent with three cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (followed by additional neoadjuvant chemotherapy) had an incidence of symptomatic heart failure of less than 2 percent and any left ventricular ejection fraction decrease of less than 3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/17\">",
"       17",
"      </a>",
"      ]. This was less than the incidence of trastuzumab-related cardiotoxicity in the adjuvant trials where trastuzumab was given concurrently with paclitaxel after completion of doxorubicin, which may have been due to the lower cumulative dose of doxorubicin in the NOAH trial. (See",
"      <a class=\"local\" href=\"#H39983118\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We avoid concurrent extended administration of anthracyclines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , due to an increased risk of cardiotoxicity. Based upon data described above, trastuzumab concurrent with limited anthracyclines (&le;3 cycles or &le;180",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) is a potentially safe option. However, there are no data suggesting improved efficacy if trastuzumab is given concurrent with anthracyclines rather than in sequence.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    in combination with a taxane, even after an anthracycline, shows low rates of symptomatic or severe cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Likewise, trastuzumab is frequently administered concurrent with endocrine therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy without significant cardiac toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42232/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/53/25426?source=see_link\">",
"       \"Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      is associated with a risk of cardiac toxicity that is mechanistically distinct from that caused by anthracyclines. Trastuzumab-related cardiotoxicity is typically manifested by an asymptomatic decrease in the left ventricular ejection fraction (LVEF) and less commonly by clinical heart failure.",
"     </li>",
"     <li>",
"      Previous or concurrent anthracycline use and age greater than 50 years are the strongest risk factors for development of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -related cardiotoxicity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the adjuvant setting, a baseline assessment prior to starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      and serial LVEF monitoring (at 3, 6, and 12 months after initiating trastuzumab, and 18 months after initiating an anthracycline or other chemotherapy) are appropriate to screen for cardiac dysfunction. (See",
"      <a class=\"local\" href=\"#H14451831\">",
"       'Baseline evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14452747\">",
"       'Cardiac monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the metastatic setting, after a baseline assessment, LVEF is infrequently monitored in the absence of symptoms. (See",
"      <a class=\"local\" href=\"#H14451831\">",
"       'Baseline evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14452747\">",
"       'Cardiac monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      dosing for patients who develop trastuzumab-related cardiotoxicity are based upon the reduction in LVEF and patient symptoms. (See",
"      <a class=\"local\" href=\"#H95247366\">",
"       'Trastuzumab dose adjustments for cardiotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      -related cardiotoxicity is reversible in many patients and responds to standard treatment for heart failure. Many patients tolerate continued treatment or rechallenge with trastuzumab. (See",
"      <a class=\"local\" href=\"#H14457353\">",
"       'Reversibility and rechallenge'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14451604\">",
"       'Heart failure treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      can be safely administered with taxanes, radiation therapy, and endocrine therapy. (See",
"      <a class=\"local\" href=\"#H95247583\">",
"       'Acceptable concurrent treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/1\">",
"      Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/2\">",
"      Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/3\">",
"      Fi&uacute;za M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther 2009; 26 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/4\">",
"      Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/5\">",
"      Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/6\">",
"      Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/7\">",
"      Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/8\">",
"      Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28:3416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/9\">",
"      Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28:3422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/10\">",
"      Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/11\">",
"      Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/12\">",
"      Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/13\">",
"      Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/14\">",
"      Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/15\">",
"      Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29:3366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/16\">",
"      Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/17\">",
"      Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/18\">",
"      Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/19\">",
"      Spielmann M, Roch&eacute; H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27:6129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/20\">",
"      Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4:CD006243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/21\">",
"      Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/22\">",
"      Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012; 60:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/23\">",
"      Levine MN. Trastuzumab cardiac side effects: only time will tell. J Clin Oncol 2005; 23:7775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/24\">",
"      Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/25\">",
"      Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820.",
"     </a>",
"    </li>",
"    <li>",
"     Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer (abstract). Data presented at the 29th annual San Antonio Breast Cancer Symposium, December 14, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/27\">",
"      Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med 2012; 367:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/28\">",
"      Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/29\">",
"      Erickson SL, O'Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997; 124:4999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/30\">",
"      Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/31\">",
"      Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/32\">",
"      Garc&iacute;a-Rivello H, Taranda J, Said M, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 2005; 289:H1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/33\">",
"      Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99:8880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/34\">",
"      Liu FF, Stone JR, Schuldt AJ, et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2005; 289:H660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/35\">",
"      Perik PJ, de Vries EG, Gietema JA, et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 2007; 9:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/36\">",
"      Chien KR. Herceptin and the heart--a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/37\">",
"      de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/38\">",
"      Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31:459.",
"     </a>",
"    </li>",
"    <li>",
"     Rastogi P, Jeong J, Geyer CE, et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-paclitaxel compared to AC-T with trastuzumab (abstract). J Clin Oncol 2007; 25:6s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/40\">",
"      Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/41\">",
"      Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/42\">",
"      Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/43\">",
"      Serrano C, Cort&eacute;s J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/44\">",
"      Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24:4107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/45\">",
"      Tripathy D, Seidman A, Keefe D, et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2004; 5:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/46\">",
"      Mayer EL, Lin NU. Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab? J Clin Oncol 2012; 30:3769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/47\">",
"      Fox KF. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy. Br J Cancer 2006; 95:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/48\">",
"      Saad A, Abraham J. Trastuzumab and cardiac toxicity: monitoring in the adjuvant setting. Community Oncology 2007; 4:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/49\">",
"      Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28:3910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/50\">",
"      Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 2010; 28:3901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/51\">",
"      Bianchi G, Albanell J, Eiermann W, et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003; 9:5944.",
"     </a>",
"    </li>",
"    <li>",
"     Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis (abstract). J Clin Oncol 2007; 25:10s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42232/abstract/53\">",
"      Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27:5685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 774 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42232=[""].join("\n");
var outline_f41_15_42232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39982900\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39983118\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14457353\">",
"      REVERSIBILITY AND RECHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14451472\">",
"      CLINICAL GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14451831\">",
"      Baseline evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14452747\">",
"      Cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95247366\">",
"      Trastuzumab dose adjustments for cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14451604\">",
"      Heart failure treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95247583\">",
"      ACCEPTABLE CONCURRENT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/18/18733\" title=\"table 1\">",
"      Design adjuv trastuzumab trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/30/13805\" title=\"table 3\">",
"      Incid cardiotox adjuv trial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34826?source=related_link\">",
"      Adjuvant systemic therapy for older women with early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40903?source=related_link\">",
"      Treatment of metastatic breast cancer in older women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_15_42233="Overview of lower extremity peripheral nerve syndromes";
var content_f41_15_42233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of lower extremity peripheral nerve syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42233/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42233/contributors\">",
"     Seward B Rutkove, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42233/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42233/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/15/42233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H450886663\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic provides an overview of lower extremity peripheral nerve syndromes. Peripheral nerve syndromes involving the upper extremities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve roots emerge from the spinal column from the L2 to S4 levels through the neural foramina and join to form a complex entity known as the lumbosacral plexus (",
"    <a class=\"graphic graphic_figure graphicRef75983 \" href=\"mobipreview.htm?6/50/6952\">",
"     figure 1",
"    </a>",
"    ). Unlike the brachial plexus, in which the anatomy is delineated through trunks, divisions, and cords, the lumbosacral plexus has only two main components: the lumbar plexus (made up of nerve fibers from the L2 through L5 roots) and the sacral plexus (made up of nerve fibers from the S1 through S4 roots).",
"   </p>",
"   <p>",
"    The largest nerve that emerges from the lumbar plexus is the femoral nerve, which descends beneath the inguinal ligament before dividing into a number of smaller branches innervating the anterior thigh musculature and skin (",
"    <a class=\"graphic graphic_figure graphicRef72887 \" href=\"mobipreview.htm?4/0/4100\">",
"     figure 2",
"    </a>",
"    ). One pure sensory branch, the saphenous nerve, continues down the medial leg to the arch of the foot. Although the subject of some disagreement, the iliopsoas muscle is innervated by the femoral nerve or a small nerve of its own that travels alongside the femoral. The obturator nerve also emerges from the lumbar plexus, descending more medially than the femoral, exiting the pelvis through the obturator foramen where it innervates the thigh adductors and a small cutaneous area in the medial thigh.",
"   </p>",
"   <p>",
"    A small nerve, the lateral femoral cutaneous nerve, also has its origin directly from the plexus. It travels lateral to the femoral nerve underneath the inguinal ligament to innervate the skin of the lateral thigh.",
"   </p>",
"   <p>",
"    Contributions from the lower lumbar plexus and upper sacral plexus give rise to the sciatic nerve. This nerve passes through the sciatic foramen and descends the posterior aspect of the leg until it reaches the popliteal fossa, where it divides into the posterior tibial and common peroneal nerves.",
"   </p>",
"   <p>",
"    Branches from both the lumbar and sacral plexus also form the inferior and superior gluteal nerves innervating the lateral and posterior hip musculature. Branches from the sacral plexus alone converge to form the pudendal nerves, innervating the pelvic floor musculature and perineal sensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression (including neurapraxia and axonotmesis) is the most common problem that affects neuronal structures in the lower extremities. Compression can affect distal nerve segments, as occurs in tarsal tunnel syndrome or peroneal neuropathy at the fibular neck, but is even more common proximally where a herniated disc may compress a spinal nerve root.",
"   </p>",
"   <p>",
"    In its most mild form, compression may be intermittent due to positioning, with associated reversible ischemia of the nerve. One common situation is numbness along the lateral shin and dorsum of the foot after crossing the legs secondary to compression of the peroneal nerve as it passes across the fibular neck.",
"   </p>",
"   <p>",
"    Demyelination occurs as compression grows more consistent and chronic. Symptoms are usually persistent at this point, and pain and weakness may become more prominent. As compression progresses further, the distal nerve segments will no longer function and Wallerian degeneration may occur. In most severe cases, the entire distal segment of the nerve can degenerate, similar to what would be seen in a nerve transection (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Transection'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    From a physiologic standpoint, the patient will remain asymptomatic as long as all nerve impulses are transmitted through a region of compression. As ischemia or demyelination occurs, nerve conduction will first be slowed, and then eventually blocked completely. Slowing of nerve conduction has no physiological correlate; only the complete conduction block of neuronal impulses produces functional sensory loss or weakness. Conduction block of more and more nerve fibers occurs as compression worsens. Eventually almost no impulses make it through the compressed area, while distal neuronal degeneration simultaneously begins to take place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute nerve transection (also called neurotmesis) is much less common than chronic nerve compression. It can occur with leg trauma (eg, knife wounds) as the distal nerve is completely separated from the proximal portion. Unlike even severe cases of nerve compression, the basement membrane of each individual nerve cell no longer remains intact following transection; regrowth of the nerve is impossible without intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nerve ischemia/infarct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve infarction generally only occurs in relation to vasculitis and atherosclerotic disease, although it is also thought to play a role in diabetic amyotrophy (see",
"    <a class=\"local\" href=\"#H41\">",
"     'Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy'",
"    </a>",
"    below). &nbsp;Nerve infarction in patients with vasculitis causes an axonal injury pattern, typically at well defined areas of the nerve. The most common symptomatic location for a nerve infarct in the lower extremity is the sciatic nerve in the mid-thigh; more distal infarctions in the peroneal and tibial nerves also occasionally occur.",
"   </p>",
"   <p>",
"    Unlike the case of compressive neuropathy, conduction velocity slowing does not occur. The entire distal segment of the nerve degenerates within a few days of focal nerve infarction. However, since the basement membrane remains intact, regrowth of the nerve may occur with control of the underlying disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiation-induced injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation exposure, generally in the context of radiotherapy for neoplastic disease, can result in nerve damage that may not appear clinically for years after the procedure. Although more common in patients who have undergone axillary radiation therapy for breast cancer, it can also occur in the lower extremities after receiving pelvic irradiation (eg, for cervical cancer). Progressive weakness and sensory loss with marked proprioceptive dysfunction may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory processes of the nerve or roots also can cause significant problems affecting the legs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious disorders such as herpes simplex, Epstein-Barr virus, and most commonly herpes zoster virus, can produce syndromes of sensory loss and motor dysfunction.",
"     </li>",
"     <li>",
"      An idiopathic inflammatory response is responsible for the syndrome of lumbosacral plexitis.",
"     </li>",
"     <li>",
"      An inflammatory response associated with diabetes mellitus occasionally occurs, likely playing a role in diabetic radiculopathy and diabetic amyotrophy.",
"     </li>",
"     <li>",
"      Inflammation restricted to the dorsal root ganglion may occur rarely as a paraneoplastic process or associated with Sj&ouml;gren's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal degeneration of neurons is the hallmark of most axonal polyneuropathies. Gradual deterioration of neurons occurs in a distal to proximal fashion, with the longest nerves affected first. The reason proposed for this phenomenon is that the most distal segments of nerve are the most vulnerable to metabolic and toxic factors.",
"   </p>",
"   <p>",
"    Proximal degeneration of neurons also may occur in certain disorders, although this is much less common. Most concerning is a focal form of motor neuron cell loss associated with progressive weakness of an entire extremity over a period of months; this may represent a focal form of motor neuron disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450887325\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the epidemiology of lower extremity peripheral nerve syndromes are relatively limited. The most common nerve problem affecting the lower extremities is probably lumbosacral radiculopathy (",
"    <a class=\"graphic graphic_table graphicRef75974 \" href=\"mobipreview.htm?22/51/23355\">",
"     table 1",
"    </a>",
"    ). Low back pain is an extremely common complaint (significantly affecting between 40 to 80 percent of people at some time), although clinically apparent lumbosacral radiculopathy is less common, perhaps affecting 4 to 6 percent of the population at some point in their lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/1\">",
"     1",
"    </a>",
"    ]. The next most common problem, excluding polyneuropathy, is likely to be compression of the peroneal nerve at the fibular neck (",
"    <a class=\"graphic graphic_table graphicRef78221 \" href=\"mobipreview.htm?34/28/35276\">",
"     table 2",
"    </a>",
"    ). In our EMG laboratory, this diagnosis accounted for approximately 2 percent of all referrals over a one-year period. There are no published data that identify the frequency of plexopathy or other entrapment neuropathies affecting the lower extremities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms suggestive of a peripheral nerve problem are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific syndromes are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef75974 \" href=\"mobipreview.htm?22/51/23355\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78221 \" href=\"mobipreview.htm?34/28/35276\">",
"     table 2",
"    </a>",
"    ) and discussed in detail below.",
"   </p>",
"   <p>",
"    Very mild focal abnormalities of the lower extremity nerves may be identified when performing electrophysiologic testing for other purposes (eg, to look for polyneuropathy). As an example, peroneal motor conduction velocity slowing across the fibular neck segment may suggest extremely mild compression of the nerve. Lumbosacral radiculopathy is probably the most common asymptomatic problem identified, especially in older individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography (EMG) and nerve conduction studies (NCS) remain the most effective means of identifying and classifying peripheral nerve disorders affecting the lower extremity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal entrapments of the peroneal nerve are generally straightforward to determine using",
"    <span class=\"nowrap\">",
"     EMG/NCS.",
"    </span>",
"    The electromyographer looks for evidence of demyelination (conduction velocity slowing and conduction block) across likely affected segments of nerve, such as the peroneal nerve at the fibular neck. Electromyography tends to be most important for the diagnosis of radiculopathy and plays a more confirmatory role in other disorders. It will give some insight into lesion severity as well.",
"   </p>",
"   <p>",
"    In plexopathies, abnormalities are usually found in several nerves emanating from one region of the plexus. Studying conduction across the plexus is generally not performed for technical reasons; thus, the usual findings of demyelination cannot be sought. Instead, testing is confined to distal segments and a search for axon loss is pursued. As an example, in a patient with a diffuse lumbosacral plexopathy, reductions in the amplitude of the sural, superficial peroneal, and saphenous sensory responses are typical. Needle examination may disclose fibrillation potentials and positive sharp waves in multiple lower extremity muscles not confined to one limb or myotome.",
"   </p>",
"   <p>",
"    In radiculopathy, sensory responses are spared since the lesion is proximal to the dorsal root ganglion. Motor studies are usually also normal, although L5 radiculopathy can produce a reduction in amplitude of the extensor digitorum brevis motor response when stimulating the peroneal nerve. Usually abnormalities are identified only on needle examination of the muscles derived from the affected roots.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is the best first study to obtain in some patients. As an example, magnetic resonance imaging of the lumbosacral spine is reasonable in a patient with radiating back pain, sensory loss over the dorsum of the foot, and weakness in L5 muscles. However, in most situations a patient's complaints are more nondescript. Pain may be nonfocal, weakness minimally present, and no fixed sensory loss identified. In these situations",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    is probably the first test to pursue and, depending upon the results, imaging of the appropriate area can be performed secondarily.",
"   </p>",
"   <p>",
"    The utility of plain films generally is limited, with a few exceptions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain films of the lumbosacral spine will give a sense of the degree of degenerative change; loss of disc space at one level may suggest a herniated nucleus pulposus. Osteolytic lesions also can be identified.",
"     </li>",
"     <li>",
"      Plain films of the distal leg are rarely indicated except in cases of trauma or when a palpable mass lesion is present.",
"     </li>",
"     <li>",
"      Plain films of the back generally are reserved for patients with nonfocal, nonradiating back pain with no significant neurologic compromise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI has become the mainstay of most neurologic imaging. In lumbosacral spine disease, specifics of disc herniation, degeneration, and degree of compression of a specific nerve root has made this tool invaluable, especially when considering a surgical option. In one study, the degree of herniation on MRI was correlated with the patient's symptoms and improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/2\">",
"     2",
"    </a>",
"    ]. On the other hand, another report that compared MRI and EMG in the diagnosis of radiculopathy found that the two procedures were in agreement only 60 percent of the time, with a significant abnormality being identified on one test and not the other in 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with idiopathic plexopathies, one-time imaging is probably warranted to exclude the possibility of a mass lesion in the region, especially in those with worsening symptoms or a history of neoplastic disease. MRI of nerves is occasionally performed after",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    has suggested a specific location for the problem, such as a mid-thigh sciatic neuropathy.",
"   </p>",
"   <p>",
"    CT has some utility for patients with pacemakers or who cannot use an MRI for other reasons. CT combined with myelography gives useful information regarding nerve roots in patients with lumbosacral disc disease. CT can also give better information about bony elements than MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is usually of limited value in patients presenting with focal symptoms affecting a limb. However, some tests are worth considering:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting glucose and glycohemoglobin in patients with possible diabetic amyotrophy, idiopathic radiculopathy, polyneuropathy",
"     </li>",
"     <li>",
"      Lyme titers in patients with polyradiculopathy, especially in endemic areas",
"     </li>",
"     <li>",
"      Hereditary neuropathy with predisposition to pressure palsy gene test in patients with multiple mononeuropathies (usually affecting at least two to three extremities)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with mononeuropathy multiplex, many other laboratory studies are warranted in an attempt to identify the underlying disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture is warranted in patients with unusual presentations of radiculopathy or where distinguishing between a radiculopathy and lumbosacral plexopathy is not straightforward. The cerebrospinal fluid (CSF) should be examined for evidence of inflammation (including elevated CSF protein and mononuclear cells) and serologic testing for Lyme disease, syphilis, and cytomegalovirus (CMV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PERONEAL NERVE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Compression at the fibular neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent site of injury to the common peroneal nerve is just below the knee as the nerve wraps around the lateral aspect of the fibula, immediately before dividing into its deep and superficial branches. Compression at this site is frequently produced by external pressure on the nerve due to prolonged lying, such as during surgery or prolonged hospitalization. Crossing the legs, protracted squatting, and leg casts also can cause compression at this site.",
"   </p>",
"   <p>",
"    The typical clinical presentation of common peroneal neuropathy at the fibular neck is acute foot drop (difficulty dorsiflexing the foot against resistance or gravity). Patients describe the foot as limp; there is a tendency to trip over it unless they compensate by flexing the hip higher when walking, producing what is called a \"steppage\" gait. Patients may also complain of paresthesias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory loss over the dorsum of the foot and lateral shin (superficial peroneal nerve territory). In one study, 79 percent of 103 patients with common peroneal neuropathy complained of sensory loss; pain was relatively infrequent, affecting only 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination typically reveals weakness in foot dorsiflexion and foot eversion (deep and superficial peroneal nerve-innervated, respectively), with normal inversion and plantar flexion (posterior tibial nerve). Sensory disturbance is confined to the dorsum of the foot, including the web space between digits 1 and 2 and the lateral shin. Reflexes are normal.",
"   </p>",
"   <p>",
"    Electromyography and nerve conduction studies",
"    <span class=\"nowrap\">",
"     (EMG/NCS)",
"    </span>",
"    are very useful for identifying peroneal neuropathy at the fibular neck; conduction block on peroneal motor studies may be identified at the site, even in the acute setting. Reduction in distal motor and sensory response amplitudes can occur in severe cases, suggesting axonal injury. Needle examination discloses abnormalities in the deep and superficial peroneal nerve innervated muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to upper extremity neuropathies, treating compression neuropathies of the lower extremity is often not possible or of limited benefit. In patients with a peroneal neuropathy at the fibular neck, for example, no specific treatment is available other than removing pressure on the nerve (such as extra cushioning while sleeping and avoidance of crossing the legs during the day). An ankle-foot orthosis splint, to keep the foot dorsiflexed, should be used until active movement has recovered. Physical therapy progressing from passive range of movement to passive assistive, active, and active resistant exercise under supervision with a physical therapist may also be helpful. Walking is particularly important therapy.",
"   </p>",
"   <p>",
"    Prognosis depends upon the degree of dysfunction. In one study of 13 patients with idiopathic common peroneal palsy, those presenting with complete lesions (no preserved function in foot dorsiflexion and foot eversion) made no significant recovery, while patients with even mildly preserved strength recovered fully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Operative decompression can be considered for patients who do not recover on their own, although true entrapment of the peroneal nerve is uncommon. One investigator, for example, explored 26 common peroneal nerves in 23 patients; evidence for entrapment was found in only 1 of the 8 with no other apparent cause for the neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/6\">",
"     6",
"    </a>",
"    ]. Entrapment should be suspected when symptoms and signs progress and no other cause is identified. In that circumstance, surgical decompression can be successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Compression at the ankle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep peroneal nerve is rarely injured in the region of the ankle. Usually injury is due to a tight-fitting rim or strap from a shoe. Patients generally complain of pain in the region with minimal weakness and sensory disturbance involving only the web space between digits 1 and 2. Directed physical examination reveals minimal abnormalities. Nerve conduction studies may demonstrate a prolonged distal motor latency; on needle electromyography abnormalities can be identified in extensor digitorum brevis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the common peroneal nerve occasionally occurs in the popliteal fossa, immediately after the division of the sciatic nerve into posterior tibial and common peroneal nerves. Baker's cysts are the most common cause in this region. Nerve infarctions due to mononeuropathy multiplex also occur in the area of the knee and, at least acutely, may be difficult to distinguish from a compressive neuropathy at the fibular neck, although pain is prominent in vasculitic lesions and is minimal in compressive ones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POSTERIOR TIBIAL NERVE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Tarsal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tarsal tunnel syndrome refers to tibial nerve compression in the region of the ankles as the nerve passes under the transverse tarsal ligament (",
"    <a class=\"graphic graphic_figure graphicRef50910 \" href=\"mobipreview.htm?36/48/37647\">",
"     figure 3",
"    </a>",
"    ). Beneath this retinaculum (or laciniate ligament) lies a tunnel containing the tendons of the flexor digitorum longus and flexor hallucis longus muscles, the vascular bundle, the posterior tibial nerve, and the medial and lateral plantar nerves. The most common cause of tarsal tunnel syndrome is a fracture or dislocation involving the talus, calcaneus, or medial malleolus. In these cases, scar tissue, bone or cartilage fragments, or bony spurs may be found compressing the nerve. Etiologies other than injury include rheumatoid arthritis, other causes of inflammation, and tumors.",
"   </p>",
"   <p>",
"    Patients with tarsal tunnel syndrome typically present with aching, burning, numbness, and tingling involving the sole of the foot, the distal foot, the toes, and occasionally the heel. The pain may radiate up to the calf or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/8\">",
"     8",
"    </a>",
"    ]. The discomfort is often most irritating at night, may be worse after standing, and sometimes leads to the desire to remove the shoes, even while driving.",
"   </p>",
"   <p>",
"    Examination may disclose a prominent Tinel's sign over the nerve posterior to the medial malleolus with sensory loss over the plantar surface of the foot,",
"    <strong>",
"     not",
"    </strong>",
"    extending onto the dorsal foot. Atrophy of intrinsic foot musculature will be present only if the nerve injury is severe.",
"   </p>",
"   <p>",
"    Although it is a common consideration in patients presenting with foot and ankle pain, making a definite diagnosis of this disorder is difficult. Electrodiagnostic testing may reveal prolonged tibial motor distal latencies and slowing of conduction velocities across the flexor retinaculum when recording from the medial and lateral plantar nerve territories. Comparison studies to the unaffected extremity may be helpful in this regard. EMG evaluation is of limited utility since the intrinsic foot muscles normally have mild degrees of denervation and chronic reinnervation. Again, comparison to the appearance of foot musculature on the contralateral limb is usually necessary.",
"   </p>",
"   <p>",
"    In general, true tarsal tunnel syndrome is most commonly diagnosed in patients with a clear history of antecedent foot trauma. Without such a history, \"idiopathic\" tarsal tunnel syndrome, unlike carpal tunnel syndrome, is quite rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptoms of tarsal tunnel syndrome and no history of trauma should be given a trial of conservative therapy, including NSAIDs, shoe modification, and in some cases orthotics. If the patient does not respond, corticosteroid injection may provide relief and can be useful diagnostically.",
"   </p>",
"   <p>",
"    Decompression of the tibial nerve at the ankle is effective in some patients who truly have a documented entrapment and have failed conservative therapy. In one retrospective study, 47 patients over a 10-year period underwent surgical decompression of the tibial nerve at the ankle after an average 16 months of conservative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/9\">",
"     9",
"    </a>",
"    ]. The majority (81 percent) had confirmatory nerve conduction abnormalities with suggestive clinical findings (including a Tinel's sign at the ankle). In general, patients noted an improvement in symptoms, with 72 percent stating that they were satisfied with the surgical outcome. However, the perioperative complication rate was very high at 30 percent.",
"   </p>",
"   <p>",
"    Other surgical studies have noted more mixed results. The most favorable outcomes appear to occur with a short history of illness, the presence of a ganglion, no history of sprains, and light work demands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibial nerve is rarely affected more proximally due to its deep location within the lower leg. Like the peroneal nerve, however, occasional compressive symptoms can occur in the popliteal fossa, such as from a Baker's cyst.",
"   </p>",
"   <p>",
"    Isolated medial and lateral plantar neuropathies may also occur within the foot itself. These often are due to trauma, fibrosis, or possibly entrapment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SCIATIC NERVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sciatic neuropathy occurs due to a variety of causes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 73 patients who fulfilled strict electrophysiologic criteria for sciatic neuropathy, hip surgery was the cause in 22 percent, acute external compression in 14 percent, infarction in 10 percent, gunshot wound in 10 percent, hip",
"      <span class=\"nowrap\">",
"       fracture/dislocation",
"      </span>",
"      in 10 percent, femur fracture in 4 percent, possible contusion in 4 percent, and unclear etiology in 16 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report of sciatic nerve lesions in 53 children, the etiologies included trauma in 25 percent, iatrogenic causes (orthopedic and other surgeries) in 25 percent, tumor in 13 percent, prolonged external compression and immobilization in 11 percent, vascular in 9 percent, idiopathic and progressive in 8 percent, unknown (presumed viral) in 6 percent, and infantile and nonprogressive in 4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Compression/trauma in the sciatic notch/gluteal region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause for compression or injury to the sciatic nerve in this region is trauma, including hip dislocation, fracture, or replacement. Other etiologies include wayward buttock injections, compression by external sources such as prolonged bed rest (eg, coma), and any deep-seated mass in the pelvis, including hematomas.",
"   </p>",
"   <p>",
"    The piriformis syndrome is an occasional contributor to sciatic nerve injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/13\">",
"     13",
"    </a>",
"    ]. In this disorder, compression of the sciatic nerve occurs in the region of the sciatic notch as the nerve comes in close contact with a hypertrophied piriformis muscle.",
"   </p>",
"   <p>",
"    Sciatic nerve lesions also have been reported as an unusual complication of cardiac surgery. In one study, six cases of postcardiac surgery sciatic neuropathy were identified over a 15 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/8\">",
"     8",
"    </a>",
"    ]. An intraaortic balloon pump was used on the ipsilateral side in four of these instances. The majority of affected patients also had symptomatic peripheral vascular disease.",
"   </p>",
"   <p>",
"    In addition to pain, patients with significant injury to the sciatic nerve in this region also complain of weakness affecting most of the lower leg musculature, including the hamstrings. Hip flexion, extension, abduction and adduction, and knee extension are normal. Sensory loss involves the entire peroneal, tibial, and sural territories. In the lower leg, however, the medial calf and arch of the foot may be spared secondary to innervation by the preserved saphenous nerve (a branch of the femoral nerve). Sensation is also spared above the knee both anteriorly and posteriorly. The knee jerk is normal, but the ankle jerk is unobtainable.",
"   </p>",
"   <p>",
"    Compression of the sciatic nerve may not produce significant abnormalities on EMG unless it is relatively severe. Reduced peroneal and sural sensory responses and a normal saphenous sensory response are identified in more severe cases. Tibial and peroneal motor response amplitudes also are reduced. A",
"    <span class=\"nowrap\">",
"     denervation/reinnervation",
"    </span>",
"    pattern in muscles supplied by the nerve, including the hamstrings, is typical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Lesions in the mid-thigh",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sciatic nerve lesions less commonly occur in the mid-thigh. Etiologies include compression due to a femur fracture or mass, or ischemic nerve infarction.",
"   </p>",
"   <p>",
"    Symptoms and signs may be very similar to those caused by sciatic nerve injury in the gluteal region except that some sparing of hamstring function is likely. Interestingly, the predominant abnormalities in sciatic nerve function often affect the peroneal more than the tibial division, even though the entire sciatic nerve is affected. This is often true electrophysiologically as well as clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of sciatic neuropathy is generally favorable. In one study, patients had a 75 percent overall likelihood of good recovery without treatment over a three-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/11\">",
"     11",
"    </a>",
"    ]. Absence of paralysis in foot plantar and dorsiflexion at initial evaluation was a favorable prognostic sign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     FEMORAL NERVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the femoral nerve is relatively uncommon due to its position within the pelvis and anterior thigh. Nevertheless, hip or pelvic fractures or masses within the iliacus (such as hematoma) can sometimes result in a femoral neuropathy. The true incidence of iatrogenic femoral nerve injury is unknown, but the syndrome is a recognized complication of childbirth and procedures such as hip replacement, abdominal and pelvic surgery or laparoscopy, inguinal lymph node biopsy, femoral nerve block, and femoral artery puncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. One report suggested that femoral neuropathy was caused by prolonged maintenance of the lithotomy position itself with compression of the inguinal ligament upon the nerve, rather than a specific surgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition to compression, other potential mechanisms of iatrogenic femoral nerve injury include transection, diathermy, toxic injury, and ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with diabetes mellitus occasionally develop spontaneous femoral neuropathies. However, it is debated whether this simply represents a more limited form of diabetic amyotrophy (see",
"    <a class=\"local\" href=\"#H41\">",
"     'Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy'",
"    </a>",
"    below). The mechanism of this is presumably nerve infarction.",
"   </p>",
"   <p>",
"    On examination, patients with significant femoral neuropathies develop weakness involving the quadriceps muscle group with sparing of adduction, which is mediated by the obturator nerve. One argued point is whether or not the iliopsoas is innervated by the femoral nerve or a direct branch of the plexus; regardless of the strict answer, it is clear that some patients with what appear to be isolated femoral neuropathies also have prominent iliopsoas weakness. In addition to muscle weakness, sensory loss over the anterior thigh and most of the medial thigh is typical. The sensory loss extends down the medial shin to the region of the arch of the foot due to saphenous nerve dysfunction. The knee jerk generally decreases or becomes unobtainable.",
"   </p>",
"   <p>",
"    Occasionally the infrapatellar branch of the saphenous nerve is damaged due to mild trauma or knee operations. This produces the syndrome of",
"    <strong>",
"     gonyalgia paresthetica",
"    </strong>",
"    , which includes sensory loss in a several centimeter diameter patch below the knee with intermittent lancinating pains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Needle electromyography may be helpful in demonstrating isolated involvement of muscles innervated by the femoral nerve without involvement of obturator innervated muscles or paraspinals. A reduced or absent saphenous sensory response will also help confirm the presence of a femoral neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435194098\">",
"    <span class=\"h2\">",
"     Management and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of femoral nerve injury is mainly supportive and includes physical therapy, but depends in part upon the mechanism and severity of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A compressive hematoma may require drainage with correction of any underlying coagulopathy. Analgesia is indicated for patients with significant pain. Surgical exploration and nerve repair or grafting may be needed for patients with suspicion of traumatic direct nerve injury, such as transection or ligation.",
"   </p>",
"   <p>",
"    The prognosis of incomplete femoral nerve injury is generally good [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The degree of axon loss as determined by electrodiagnostic studies is an important prognostic indicator. In one series of 31 patients with unilateral femoral neuropathy, excellent, satisfactory, and poor outcomes were observed in 31, 34, and 31 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/19\">",
"     19",
"    </a>",
"    ]. The only factor associated with prognosis was the estimate of axonal loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     LATERAL FEMORAL CUTANEOUS NERVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral femoral cutaneous nerve is a small sensory nerve that is a direct branch of the lumbar plexus. Entrapment of the nerve as it traverses below the inguinal ligament produces the common syndrome of meralgia paresthetica. Patients generally complain of paresthesias and pain that radiates down the lateral aspect of the thigh toward the knee. The pain can be quite significant. In more advanced cases, fixed sensory loss on the lateral thigh occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39061?source=see_link\">",
"     \"Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients are especially predisposed to developing meralgia paresthetica, including obese people who wear tight fitting belts and postpartum women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/14\">",
"     14",
"    </a>",
"    ]. In others no obvious cause is identified.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    generally have a limited role in the evaluation of this disorder. Studies may be relatively normal in mild cases. A reduced response amplitude is generally evidence for a lesion severe enough to produce axon loss. Needle electromyography is performed to help exclude radiculopathy or plexopathy.",
"   </p>",
"   <p>",
"    Conservative measures such as weight loss and avoiding external pressure over the inguinal ligament (eg, due to supporting heavy materials on the thigh) are usually effective. Local anesthetic injection and nonsteroidal antiinflammatory drugs may also be helpful. In one study, 91 percent of 277 patients with this problem responded well to conservative therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/20\">",
"     20",
"    </a>",
"    ]. In those who did not, neurolysis was almost always effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     OBTURATOR NERVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mononeuropathies of the obturator nerve are uncommon. They present with pain, weakness in leg adduction, and sensory loss over a small area in the medial thigh. There is no compelling evidence of a true obturator entrapment neuropathy caused by a narrow obturator foramen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/21\">",
"     21",
"    </a>",
"    ]. However, obturator neuropathy does occur secondary to pelvic trauma or surgery. In addition, one study suggested that isolated obturator neuropathy can be the sole manifestation of pelvic cancer, most commonly transitional cell carcinoma of the bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=see_link&amp;anchor=H14#H14\">",
"     \"Nerve injury associated with pelvic surgery\", section on 'Obturator nerve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     LUMBOSACRAL PLEXOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral plexopathy is reviewed briefly here, and discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link\">",
"     \"Lumbosacral plexus syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lumbosacral plexopathies (LSP) usually present with diffuse weakness of the affected lower extremity, although a patchy distribution of weakness may occur. Weakness can involve the femoral and sciatic territories depending upon whether the lumbar and sacral plexi are both involved. Lumbar plexus lesions tend to cause weakness of hip flexion and adduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    knee extension. Lumbosacral trunk and upper sacral plexus lesions result in foot drop or flail foot, depending on the extent of involvement, and weakness of knee flexion or hip abduction.",
"   </p>",
"   <p>",
"    The causes of LSP are numerous and diverse (",
"    <a class=\"graphic graphic_table graphicRef52765 \" href=\"mobipreview.htm?25/61/26587\">",
"     table 3",
"    </a>",
"    ). Important considerations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link\">",
"       \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neoplastic invasion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H13#H13\">",
"       \"Lumbosacral plexus syndromes\", section on 'Neoplastic invasion'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Radiation therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H16#H16\">",
"       \"Lumbosacral plexus syndromes\", section on 'Radiation plexopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Trauma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H19#H19\">",
"       \"Lumbosacral plexus syndromes\", section on 'Trauma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pregnancy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H21#H21\">",
"       \"Lumbosacral plexus syndromes\", section on 'Peripartum plexopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgery (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H23#H23\">",
"       \"Lumbosacral plexus syndromes\", section on 'Postoperative plexopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vascular conditions, particularly retroperitoneal hematoma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H24#H24\">",
"       \"Lumbosacral plexus syndromes\", section on 'Vascular causes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H25#H25\">",
"       \"Lumbosacral plexus syndromes\", section on 'Retroperitoneal hematoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parainfectious, inflammatory, and infiltrative disorders (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H27#H27\">",
"       \"Lumbosacral plexus syndromes\", section on 'Infectious, inflammatory, and infiltrative causes'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Information from the clinical setting and the physical and neurologic examinations should be used to direct the diagnostic evaluation of LSP, which may include laboratory studies, neuroimaging, and electrodiagnostic studies. MRI is the imaging method of choice for plexus evaluation given its versatility and improved anatomical detail. However, CT may be more readily available than MRI and remains the optimal choice for those with contraindications to MRI. Electrodiagnostic studies can help differentiate LSP from lumbosacral radicular and individual nerve syndromes, and may also provide clues to the intraplexus location and possible etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=see_link&amp;anchor=H14#H14\">",
"     \"Lumbosacral plexus syndromes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     DIABETIC AMYOTROPHY AND IDIOPATHIC LUMBOSACRAL RADICULOPLEXUS NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy and the similar condition known as idiopathic lumbosacral radiculoplexus neuropathy are discussed briefly here and reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic amyotrophy is not a pure lumbosacral plexopathy because it also affects the lumbosacral nerve roots and peripheral nerves. The most likely cause of diabetic amyotrophy and the clinically similar condition of idiopathic lumbosacral radiculoplexus neuropathy is ischemic injury from a nonsystemic microvasculitis.",
"   </p>",
"   <p>",
"    Diabetic amyotrophy typically occurs in patients with type 2 diabetes mellitus. The traditional features include the asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss. Progression occurs over months and is followed by partial recovery in most patients. However, onset in the distal leg is not uncommon. Furthermore, the condition becomes more widespread and symmetric with time. In nearly all cases, the symptoms and signs progress to affect the contralateral limb and the distal legs. Thoracic and upper limb involvement has also been observed as part of the syndrome of diabetic amyotrophy in a minority of patients. Some have symptoms and signs suggesting a thoracic radiculopathy, a brachial plexopathy, or mononeuropathies of the ulnar and median nerves. Most upper limb symptoms occur in association with lumbosacral plexus involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link&amp;anchor=H3#H3\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Idiopathic lumbosacral radiculoplexus neuropathy is similar to diabetic amyotrophy with respect to its clinical features, prognosis, and management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link&amp;anchor=H5#H5\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Idiopathic lumbosacral radiculoplexus neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of diabetic amyotrophy is mainly based upon the presence of suggestive clinical features in a patient with known or newly diagnosed diabetes mellitus. Appropriate laboratory investigations, particularly electrodiagnostic studies, and neuroimaging in select patients, are useful to exclude other peripheral and central nervous system etiologies as a cause of the neurologic symptoms and signs. In patients who do not have diabetes, idiopathic lumbosacral radiculoplexus neuropathy is the primary consideration in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link&amp;anchor=H6#H6\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While clinical improvement is the rule with diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy, most patients do not recover completely. There are no proven effective treatments for these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link&amp;anchor=H10#H10\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=see_link&amp;anchor=H11#H11\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     LUMBOSACRAL RADICULOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral radiculopathy is a condition in which a disease process affects the function of one or more lumbosacral nerve roots. It is reviewed briefly in the following sections, and discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Structural spine disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral radiculopathy can have variable presentations. In the young individual with an acute herniated disc, severe radiating pain, sensory loss, and weakness in muscles of the myotome of the affected nerve root can occur (",
"    <a class=\"graphic graphic_figure graphicRef50419 \" href=\"mobipreview.htm?10/36/10822\">",
"     figure 4",
"    </a>",
"    ). A specific injury or inciting event may be recalled. Acute disc herniation is uncommon in older individuals; spondylosis secondary to disc degeneration, calcification, and osteophytes is more typical. Generally these patients present with sensory loss, weakness, and pain that can be quite severe, although in some the pain is relatively limited. Unlike the acute herniated disc of a young person in whom only one root is affected, involvement of multiple myotomes is usually present in older people. Regardless of age, coughing, sneezing, or leg straightening can exacerbate symptoms. The symptoms and signs of lumbosacral radiculopathy vary according to level:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       L2-L4 radiculopathy",
"      </strong>",
"      &ndash; Localizing a mid-lumbar radiculopathy to a specific nerve root can be difficult clinically and electrodiagnostically. Thus, these radiculopathies are generally considered as a group. Acute back pain is the most common presenting complaint, often radiating around the anterior aspect of the leg down into the knee and possibly down to the foot. On examination, strength can be reduced in hip flexion, knee extension, and leg adduction. Sensation may be reduced over the anterior thigh down the medial aspect of the shin. A reduced knee jerk is commonly present in more severe lesions.",
"     </li>",
"     <li>",
"      <strong>",
"       L5 radiculopathy",
"      </strong>",
"      &ndash; L5 radiculopathy is by far the most common radiculopathy affecting the lumbosacral spine. It often presents with back pain that radiates down the lateral aspect of the leg into the foot. On examination, strength can be reduced in foot dorsiflexion, toe extension, foot inversion, and foot eversion. Mild weakness in leg abduction may also be evident in severe cases due to involvement of gluteus minimus and medius. Atrophy may be subtle; it is most readily observed in extensor digitorum brevis. Sensory loss is confined to the lateral shin and dorsum of the foot. Reflexes are generally normal.",
"     </li>",
"     <li>",
"      <strong>",
"       S1 radiculopathy",
"      </strong>",
"      &ndash; In S1 radiculopathy, pain radiates down the posterior aspect of the leg into the foot from the back. On examination, strength may be reduced in leg extension (gluteus maximus), foot inversion, plantar flexion, and toe flexion. Sensation is generally reduced on the posterior aspect of the leg and the lateral foot. Ankle jerk loss is typical.",
"     </li>",
"     <li>",
"      <strong>",
"       S2-S4 radiculopathy",
"      </strong>",
"      &ndash; Structural radiculopathies at these lower levels are distinctly less common than other lumbosacral radiculopathies, unless a large central disc is compressing the nerve roots intrathecally at a higher level (eg, L5). Patients can present with sacral or buttock pain that radiates down the posterior aspect of the leg or into the perineum. Weakness may be minimal, with urinary and fecal incontinence as well as sexual dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of structural spine disease depends upon the severity of the lesion. Acute lumbosacral radiculopathy caused by disc herniation or foraminal stenosis is often extremely painful, but the likelihood of spontaneous improvement is high. Symptoms limited to pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory loss should first be managed conservatively. The treatment of acute lumbosacral radiculopathy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5655?source=see_link\">",
"     \"Acute lumbosacral radiculopathy: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with persistent disabling lumbar radicular symptoms (eg, recalcitrant pain, leg weakness, or impairment of",
"    <span class=\"nowrap\">",
"     bowel/bladder",
"    </span>",
"    function) who desire surgery and are good candidates, open discectomy or microdiscectomy are both reasonable options. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=see_link&amp;anchor=H6#H6\">",
"     \"Subacute and chronic low back pain: Surgical treatment\", section on 'Lumbar disc prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More general issues related to the management of low back pain, particularly nonspecific and musculoskeletal low back pain, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Nonstructural disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonstructural causes are occasionally responsible for symptoms of lumbosacral radiculopathy, although this is far less common than structural spine disease. Neoplastic or infectious etiologies of radiculopathy require prompt mechanism-specific treatment.",
"   </p>",
"   <p>",
"    The most notable nonstructural syndrome is cytomegalovirus polyradiculopathy in immunocompromised individuals. Patients with this disorder present with a rapidly progressive picture of usually asymmetric, bilateral radiating back and leg pain, weakness, incontinence, and sensory loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7623?source=see_link\">",
"     \"AIDS-related cytomegalovirus neurologic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpes simplex may also produce a radicular syndrome of pain and paresthesias in a saddle distribution.",
"   </p>",
"   <p>",
"    Focal tumor such as schwannoma, or more diffuse tumor such as carcinomatous meningitis, also can cause radicular problems. Inflammatory or infectious processes including Lyme disease, syphilis, or sarcoidosis are rarely responsible.",
"   </p>",
"   <p>",
"    Diabetes mellitus has been associated with",
"    <span class=\"nowrap\">",
"     inflammatory/ischemic",
"    </span>",
"    radiculopathies in the lumbosacral region. Patients generally present with what appears to be an acute structural nerve root lesion with pain and some associated sensory loss and weakness. No lesion is identifiable on imaging studies. Pain tends to be out of proportion to other objective signs. Lumbar puncture may demonstrate an elevated protein and a mild lymphocytosis. Resolution of this problem within weeks is typical. Nevertheless, evaluating for diabetes in patients with radiculopathy of unknown etiology is reasonable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16934?source=see_link\">",
"     \"Epidemiology and classification of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identifying and treating the underlying disease is most important with any of the unusual forms of inflammatory radiculopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450887255\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyneuropathies, both axonal and demyelinating, often preferentially affect the lower extremities before beginning to seriously produce symptoms in the upper extremities. Distal sensory loss, weakness, gait instability, and",
"    <span class=\"nowrap\">",
"     pain/burning",
"    </span>",
"    in the feet bilaterally are common symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Mononeuropathy multiplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic lesions affecting multiple nerves may produce a complex clinical picture. More widespread nerve involvement is present in most patients, including in the legs. Nevertheless, in a sizable proportion of people this disorder may present with a significant \"axonal polyneuropathy\" type picture in the legs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42233/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the underlying disease remains the rule. Recovery can be excellent despite initial severe nerve damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Inflammatory demyelinating conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain disorders occasionally present initially affecting one extremity. Chronic inflammatory demyelinating polyradiculoneuropathy may do likewise. However, careful examination will reveal other abnormalities such as global hypo- or areflexia or subtle weakness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Zoster radiculoganglionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with herpes zoster may develop, in addition to a painful rash, weakness and sensory loss in a nerve distribution close to that of the rash. Inflammation involves the nerve roots and dorsal root ganglion, potentially producing prominent neurogenic injury.",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    may reveal significant sensory and motor abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/8/32898?source=see_link\">",
"       \"Patient information: Radiculopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450886655\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major mechanisms of lower extremity peripheral nerve injury are compression, transection, ischemia, radiation exposure, inflammation, and neuronal degeneration. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common nerve problem affecting the lower extremities is probably lumbosacral radiculopathy. The clinical features of specific lower extremity nerve syndromes are summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef75974 \" href=\"mobipreview.htm?22/51/23355\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78221 \" href=\"mobipreview.htm?34/28/35276\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H450887325\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electromyography (EMG) and nerve conduction studies (NCS) are useful for identifying and classifying peripheral nerve disorders affecting the lower extremity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical clinical presentation of common peroneal neuropathy at the fibular neck is acute foot drop. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Peroneal nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tarsal tunnel syndrome refers to tibial nerve compression in the region of the ankles as the nerve passes under the transverse tarsal ligament (",
"      <a class=\"graphic graphic_figure graphicRef50910 \" href=\"mobipreview.htm?36/48/37647\">",
"       figure 3",
"      </a>",
"      ). Patients typically present with aching, burning, numbness, and tingling involving the sole of the foot, the distal foot, the toes, and occasionally the heel. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Posterior tibial nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sciatic neuropathy occurs due to a variety of causes. In addition to pain, patients with sciatic nerve injury in the sciatic",
"      <span class=\"nowrap\">",
"       notch/gluteal",
"      </span>",
"      region complain of weakness affecting most of the lower leg musculature. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Sciatic nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Femoral neuropathy also occurs due to a number of causes and typically results in weakness involving the quadriceps with sparing of adduction. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Femoral nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateral femoral cutaneous nerve entrapment as it traverses below the inguinal ligament produces the syndrome of meralgia paresthetica, characterized by paresthesia and pain that radiates down the lateral aspect of the thigh toward the knee. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Lateral femoral cutaneous nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mononeuropathies of the obturator nerve are uncommon. They present with pain, weakness in leg adduction, and sensory loss over a small area in the medial thigh. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Obturator nerve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbosacral plexopathies usually present with diffuse weakness of the affected lower extremity, although a patchy distribution of weakness may occur. The causes are numerous and diverse (",
"      <a class=\"graphic graphic_table graphicRef52765 \" href=\"mobipreview.htm?25/61/26587\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Lumbosacral radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy often present with asymmetric, focal onset of pain followed by weakness involving the leg, with associated autonomic failure and weight loss. Progression occurs over months and is followed by partial recovery in most patients. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbosacral radiculopathy is a condition in which a disease process affects the function of one or more lumbosacral nerve roots. The most common etiology is nerve root compression caused by a disc herniation or spinal stenosis. The symptoms and signs vary according to level (",
"      <a class=\"graphic graphic_table graphicRef75974 \" href=\"mobipreview.htm?22/51/23355\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Lumbosacral radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional lower extremity peripheral nerve syndromes include polyneuropathy, mononeuropathy multiplex, inflammatory demyelinating neuropathies, and zoster radiculoganglionitis. (See",
"      <a class=\"local\" href=\"#H450887255\">",
"       'Miscellaneous'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/1\">",
"      Frymoyer JW. Lumbar disk disease: epidemiology. Instr Course Lect 1992; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/2\">",
"      Komori H, Shinomiya K, Nakai O, et al. The natural history of herniated nucleus pulposus with radiculopathy. Spine (Phila Pa 1976) 1996; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/3\">",
"      Nardin RA, Patel MR, Gudas TF, et al. Electromyography and magnetic resonance imaging in the evaluation of radiculopathy. Muscle Nerve 1999; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/4\">",
"      Katirji MB, Wilbourn AJ. Common peroneal mononeuropathy: a clinical and electrophysiologic study of 116 lesions. Neurology 1988; 38:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/5\">",
"      Pigott TJ, Jefferson D. Idiopathic common peroneal nerve palsy--a review of thirteen cases. Br J Neurosurg 1991; 5:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/6\">",
"      Sidey JD. Weak ankles. A study of common peroneal entrapment neuropathy. Br Med J 1969; 3:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/7\">",
"      Mont MA, Dellon AL, Chen F, et al. The operative treatment of peroneal nerve palsy. J Bone Joint Surg Am 1996; 78:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/8\">",
"      McManis PG. Sciatic nerve lesions during cardiac surgery. Neurology 1994; 44:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/9\">",
"      Bailie DS, Kelikian AS. Tarsal tunnel syndrome: diagnosis, surgical technique, and functional outcome. Foot Ankle Int 1998; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/10\">",
"      Turan I, Rivero-Meli&aacute;n C, Guntner P, Rolf C. Tarsal tunnel syndrome. Outcome of surgery in longstanding cases. Clin Orthop Relat Res 1997; :151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/11\">",
"      Yuen EC, Olney RK, So YT. Sciatic neuropathy: clinical and prognostic features in 73 patients. Neurology 1994; 44:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/12\">",
"      Srinivasan J, Ryan MM, Escolar DM, et al. Pediatric sciatic neuropathies: a 30-year prospective study. Neurology 2011; 76:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/13\">",
"      Kirschner JS, Foye PM, Cole JL. Piriformis syndrome, diagnosis and treatment. Muscle Nerve 2009; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/14\">",
"      Wong CA, Scavone BM, Dugan S, et al. Incidence of postpartum lumbosacral spine and lower extremity nerve injuries. Obstet Gynecol 2003; 101:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/15\">",
"      Moore AE, Stringer MD. Iatrogenic femoral nerve injury: a systematic review. Surg Radiol Anat 2011; 33:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/16\">",
"      Al-Ajmi A, Rousseff RT, Khuraibet AJ. Iatrogenic femoral neuropathy: two cases and literature update. J Clin Neuromuscul Dis 2010; 12:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/17\">",
"      al Hakim M, Katirji B. Femoral mononeuropathy induced by the lithotomy position: a report of 5 cases with a review of literature. Muscle Nerve 1993; 16:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/18\">",
"      Massey EW. Sensory mononeuropathies. Semin Neurol 1998; 18:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/19\">",
"      Kuntzer T, van Melle G, Regli F. Clinical and prognostic features in unilateral femoral neuropathies. Muscle Nerve 1997; 20:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/20\">",
"      Williams PH, Trzil KP. Management of meralgia paresthetica. J Neurosurg 1991; 74:76.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart JD. Other mononeuropathies of the lower limb. In: Neuromuscular Function and Disease, 1st edition, Brown WF, Bolton CF, Aminoff MJ (Eds), WB Saunders Company, Philadelphia 2002. Vol 1, p.1004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/22\">",
"      Rogers LR, Borkowski GP, Albers JW, et al. Obturator mononeuropathy caused by pelvic cancer: six cases. Neurology 1993; 43:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42233/abstract/23\">",
"      Kissel JT, Mendell JR. Vasculitic neuropathy. Neurol Clin 1992; 10:761.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5278 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42233=[""].join("\n");
var outline_f41_15_42233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H450886655\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450886663\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nerve ischemia/infarct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiation-induced injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450887325\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PERONEAL NERVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Compression at the fibular neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Compression at the ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POSTERIOR TIBIAL NERVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Tarsal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SCIATIC NERVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Compression/trauma in the sciatic notch/gluteal region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Lesions in the mid-thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      FEMORAL NERVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435194098\">",
"      Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      LATERAL FEMORAL CUTANEOUS NERVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      OBTURATOR NERVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      LUMBOSACRAL PLEXOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      DIABETIC AMYOTROPHY AND IDIOPATHIC LUMBOSACRAL RADICULOPLEXUS NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      LUMBOSACRAL RADICULOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Structural spine disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Nonstructural disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450887255\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Mononeuropathy multiplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Inflammatory demyelinating conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Zoster radiculoganglionitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450886655\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5278\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5278|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/50/6952\" title=\"figure 1\">",
"      Lumbosacral plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/0/4100\" title=\"figure 2\">",
"      Nerve supply to leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/48/37647\" title=\"figure 3\">",
"      Tarsal tunnel anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/36/10822\" title=\"figure 4\">",
"      Lumbosacral dermatomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5278|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/51/23355\" title=\"table 1\">",
"      Lumbosacral radiculopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/28/35276\" title=\"table 2\">",
"      Lower extremity neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/61/26587\" title=\"table 3\">",
"      Causes of lumbosacral plexopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7623?source=related_link\">",
"      AIDS-related cytomegalovirus neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5655?source=related_link\">",
"      Acute lumbosacral radiculopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20631?source=related_link\">",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39061?source=related_link\">",
"      Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/8/32898?source=related_link\">",
"      Patient information: Radiculopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_15_42234="Gestational trophoblastic neoplasia: Staging and treatment";
var content_f41_15_42234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gestational trophoblastic neoplasia: Staging and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Elizabeth IO Garner, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/15/42234/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/15/42234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational trophoblastic disease (GTD) defines a group of conditions that arise from an aberrant fertilization event. The resulting proliferative process has the potential to develop into an invasive malignant neoplasm. The spectrum of GTD includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hydatidiform mole (a molar pregnancy, which can be complete or partial)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Persistent/invasive",
"      </span>",
"      mole",
"     </li>",
"     <li>",
"      Choriocarcinoma",
"     </li>",
"     <li>",
"      Placental site trophoblastic tumors (PSTT)",
"     </li>",
"     <li>",
"      Epithelioid trophoblastic tumor, a very rare subtype that is not discussed further in this review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=see_link&amp;anchor=H27#H27\">",
"       \"Gestational trophoblastic disease: Pathology\", section on 'Epithelioid trophoblastic tumor'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last four categories comprise gestational trophoblastic neoplasia (GTN). In general, GTN is one of the most chemotherapy-responsive and highly curable cancers, even in the setting of widespread metastatic disease.",
"   </p>",
"   <p>",
"    The staging and treatment of the three most common forms of GTN, including",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    mole, choriocarcinoma, and PSTT, will be reviewed here. Other aspects of GTD, including molar pregnancy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=see_link\">",
"     \"Gestational trophoblastic disease: Pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=see_link\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPECTRUM OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational trophoblastic neoplasia (GTN) is diagnosed when there is clinical, radiologic, pathologic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hormonal evidence of persistent or relapsed gestational trophoblastic disease. Most commonly, the diagnosis is made following a molar pregnancy, but GTN can occur after any type of gestation. Rarely, the antecedent pregnancy cannot be determined.",
"   </p>",
"   <p>",
"    Any form of GTN can metastasize. When metastases occur, the most common site is the lungs, which are involved in over 80 percent of patients. Vaginal metastases are present in up to 30 percent. Hepatic and cerebral metastases are less common, occurring in approximately 10 percent of patients. They are most commonly associated with choriocarcinoma following a nonmolar pregnancy. The majority of patients with hepatic and cerebral metastases have concurrent pulmonary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal metastasis.",
"   </p>",
"   <p>",
"    The frequency of metastatic disease at presentation varies according to the type of GTN. What follows is a brief description of the three most common types of GTN, focusing on clinical behavior and metastatic potential. The clinical features and diagnosis of these disorders is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link&amp;anchor=H8#H8\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\", section on 'Malignant GTD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Persistent/invasive",
"      </span>",
"      gestational trophoblastic mole &mdash; Approximately 20 percent of patients with a complete molar pregnancy develop an invasive or persistent mole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/1\">",
"       1",
"      </a>",
"      ]. Approximately 15 percent of patients with GTN have disease that is limited to the uterus, while 4 percent have evidence of metastatic spread at the time of diagnosis. By comparison, only 2 to 4 percent of partial moles develop GTN, which is generally nonmetastatic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/2\">",
"       2",
"      </a>",
"      ]. In the majority of cases, the disease is low risk and prognosis is good following treatment. This was demonstrated in a series of 618 women who developed GTN following a molar pregnancy in which 94 percent had low risk disease requiring single agent chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/3\">",
"       3",
"      </a>",
"      ]. The risk of relapse is also quite low following treatment; in the series above, only 18 women (three percent) relapsed.",
"      <br/>",
"      <br/>",
"      Predictors of GTN in women with a complete mole include a pre-evacuation serum level of the beta subunit of human chorionic gonadotropin (beta-hCG) &gt;100,000",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pathologic evidence of marked trophoblastic overgrowth (including excessive uterine size), and maternal age over 35 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Choriocarcinoma &mdash; Although most often a sequela of a molar pregnancy, choriocarcinoma may develop after any gestational event. Approximately 50 percent of all cases of gestational choriocarcinoma follow a hydatidiform mole, 25 percent follow a spontaneous abortion or ectopic pregnancy, and 25 percent follow a term pregnancy. GTD that develops after a nonmolar pregnancy is almost always histologically a choriocarcinoma (rarely PSTT, see below).",
"      <br/>",
"      <br/>",
"      Choriocarcinoma is a highly malignant tumor. Most lesions begin in the uterus, although many cases of extrauterine disease in the absence of a primary uterine tumor have been described. At the time of diagnosis, the majority of patients have metastatic disease, most commonly to the lung. Because of this propensity for early dissemination, most women with choriocarcinoma require combination chemotherapy to achieve disease remission.",
"     </li>",
"     <li>",
"      Placental site trophoblastic tumors &mdash; PSTTs are rare malignant neoplasms that originate from intermediate cytotrophoblast cells. PSTTs most commonly arise months to years after a term gestation, but can occur after a spontaneous abortion or a molar pregnancy. Patients present with abnormal uterine bleeding, a mass in the endometrial cavity, or amenorrhea. These tumors secrete small amounts of beta-hCG; as a result, a large tumor burden may be present before serum beta-hCG increases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Anatomic disease extent, as indicated by the FIGO tumor stage, is the strongest predictor of outcome for PSTT (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Staging and pretreatment evaluation'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. Other factors associated with a poorer outcome include older age, long interval between antecedent pregnancy and diagnosis of PSTT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"       9",
"      </a>",
"      ], large tumor burden, high pretreatment levels of beta-hCG, and the histologic features of deep myometrial invasion, high mitotic index, coagulative tumor necrosis, and tumor cells with clear cytoplasm.",
"      <br/>",
"      <br/>",
"      In contrast to choriocarcinoma, the tumor is confined to the uterus in most cases. However, as many as 30 percent of patients with PSTT present with overt metastatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. The mortality rate approaches 50 percent when metastases are present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/11\">",
"       11",
"      </a>",
"      ], but prolonged remission is possible with combination chemotherapy, particularly if it is started early (ie, within one week of surgery) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/6,12,13\">",
"       6,12,13",
"      </a>",
"      ].The stage-specific prognosis of PSTT was addressed in a population based series of 62 women diagnosed with PSTT in the United Kingdom between 1976 and 2006 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"       9",
"      </a>",
"      ]. The probability of 10-year survival for those with stage I, II, or",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      disease was 90, 52, and 49 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Following a molar pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following evacuation of a complete or partial molar pregnancy, the diagnosis of malignant GTD is usually based upon a rising or stable serum level of beta-hCG. In most such cases, the diagnosis is made clinically rather than histologically by examination of tissue.",
"   </p>",
"   <p>",
"    The specific diagnostic criteria vary around the world. Most centers in the United States utilize the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plateauing of beta-hCG levels over at least three weeks",
"     </li>",
"     <li>",
"      A 10 percent or greater rise in beta-hCG for three or more values over at least two weeks",
"     </li>",
"     <li>",
"      Persistence of beta-hCG six months after molar evacuation, or",
"     </li>",
"     <li>",
"      The histologic identification of choriocarcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment for either",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    GTN or choriocarcinoma is generally the same in that both are usually treated with chemotherapy. However, select patients with",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    GTN may also be candidates for observation. The rationale for observation is discussed below. (See",
"    <a class=\"local\" href=\"#H933460210\">",
"     'Observation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Following a nonmolar pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum hCG monitoring is not routinely performed after nonmolar pregnancies, unless the woman has had a previous molar pregnancy. Women who develop GTD after a nonmolar pregnancy usually undergo evaluation with serum hCG and ultrasound only after they become symptomatic, which may be months to years after the pregnancy.",
"   </p>",
"   <p>",
"    Because it may not be clear whether the GTD is a new event (complete or partial mole) or represents the malignant sequelae (choriocarcinoma or PSTT) of an antecedent pregnancy, histologic confirmation of ultrasound findings that are suggestive of malignant GTD is required unless there is evidence of metastatic spread. The presence of overt metastatic disease excludes the possibility of a complete or partial hydatidiform mole, and combination chemotherapy is indicated.",
"   </p>",
"   <p>",
"    A more detailed discussion of the diagnosis of choriocarcinoma or PSTT after a nonmolar pregnancy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link&amp;anchor=H16#H16\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\", section on 'Malignant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis has been confirmed, the stage of disease must be determined prior to making a decision regarding appropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STAGING AND PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with cancers other than GTN, outcome stratification and selection of appropriate therapy is typically based upon the anatomic extent of disease, which is typically ascertained by surgical staging and histologic examination of the resected specimen. The extent of disease spread in turn determines the disease \"stage\", which is then used to select treatment.",
"   </p>",
"   <p>",
"    Malignant GTD differs from this usual paradigm in a number of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prognosis is dependent upon other factors that are not reflected in the anatomic disease extent. These include age, the interval between the gestational event and the persistent disease, and serum beta-hCG concentration.",
"     </li>",
"     <li>",
"      In most cases, the diagnosis is based upon clinical and biochemical parameters; histologic confirmation and surgical staging is frequently not obtained.",
"     </li>",
"     <li>",
"      Particularly in patients with choriocarcinoma, metastatic spread to distant organs, in particular the lungs, can occur early, even in the absence of disease in the uterus or pelvis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have or who are suspected of having persistent GTN, choriocarcinoma, or PSTT must undergo a thorough evaluation prior to institution of therapy. In preparation for treatment, blood tests are obtained to assess renal and hepatic function, peripheral blood counts, and baseline serum hCG levels.",
"   </p>",
"   <p>",
"    Radiographic evaluation includes pelvic ultrasound, both to look for evidence of retained trophoblastic tissue, and to evaluate the pelvis for local spread. Chest imaging is also required, as the lungs are the most common site of metastatic disease. Chest CT is more sensitive than chest x-ray; pulmonary metastases can be detected by chest CT in up to 40 percent of patients with a negative chest x-ray [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/15\">",
"     15",
"    </a>",
"    ]. Chest CT is not mandatory, however, particularly if detection of occult pulmonary metastases will not alter the treatment plan.",
"   </p>",
"   <p>",
"    In the absence of pulmonary and vaginal involvement, brain and liver metastases are rare. Asymptomatic patients with normal chest and pelvic imaging do not require further imaging of brain or liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16\">",
"     16",
"    </a>",
"    ]. CT scan or magnetic resonance imaging (MRI) of the brain is recommended in women with persistent disease who have vaginal or lung metastases and in all patients with choriocarcinoma. Cerebral involvement can also be assessed by measuring beta-hCG levels in the cerebrospinal fluid (CSF). However, the sensitivity is not sufficient to replace brain imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As long as the clinical picture is compatible with the diagnosis of malignant GTD, metastatic lesions need not be biopsied for confirmation because of the high vascularity of most tumors and the risk for hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Staging and prognostic stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Federation of Gynecology and Obstetrics (FIGO) initially developed a four-tiered anatomic staging system for GTN based upon disease distribution:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; All patients with persistently elevated beta-hCG levels and tumor confined to the uterus.",
"     </li>",
"     <li>",
"      Stage II &mdash; The presence of tumor outside of the uterus, but limited to the vagina",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvis.",
"     </li>",
"     <li>",
"      Stage III &mdash; Pulmonary metastases with or without uterine, vaginal, or pelvic involvement.",
"     </li>",
"     <li>",
"      Stage IV &mdash; All other metastatic sites (eg, brain, liver, kidneys, gastrointestinal tract).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All stages were further stratified as A, B or C depending on the presence or absence of one or both of two risk factors for recurrence (beta-hCG &ge;100,000",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    or the detection of disease more than six months followed termination of an antecedent pregnancy).",
"   </p>",
"   <p>",
"    Clinical or prognostic staging evolved after it was recognized that a number of clinical and prognostic factors other than anatomic site of disease involvement influence cure rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/18\">",
"     18",
"    </a>",
"    ]. In 2002, FIGO approved a revision of the staging system for GTN that was subsequently adopted by the American Joint Committee on Cancer (AJCC) (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/14,19-21\">",
"     14,19-21",
"    </a>",
"    ]. The basic FIGO stages I to IV were retained to describe the anatomic distribution of disease. The prior A, B, and C risk modifier subgroups were eliminated, and replaced by a modification of the World Health Organization (WHO) scoring system called the Prognostic Scoring Index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its prognostic utility, the revised staging system is also capable of predicting which patients are likely to respond poorly to single-agent chemotherapy. A prognostic score of 7 or higher is considered a high-risk score; all of these patients are more likely to be resistant to single agent therapy and require combination chemotherapy. Patients with scores under 7 are considered low-risk and can usually be managed using single-agent chemotherapy.",
"   </p>",
"   <p>",
"    The benefit of using the prognostic score to distinguish between clinically high-risk and low-risk disease applies primarily to FIGO stage II and III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. The prognostic score adds little to the selection of treatment for women with FIGO stage I or stage IV disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, women with FIGO stage I disease generally have low-risk scores, and &gt;90 percent achieve remission with single-agent chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The majority of patients with FIGO stage IV disease have high-risk scores and are resistant to single-agent chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/22,26\">",
"       22,26",
"      </a>",
"      ]. Most have choriocarcinoma following a nonmolar pregnancy; they often have a delayed diagnosis and large tumor burden.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic utility of the scoring index for patients with PSTT is less certain; some authors recommend treatment adapted to disease stage alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H501922995\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment takes into account the stage and risk score as defined above. While many patients diagnosed with malignant GTD will require single-agent or combination chemotherapy, some may be candidates for observation. These options are discussed below. An overview of treatment by stage is also provided below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Overview of treatment by stage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933460210\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    gestational trophoblastic neoplasia (GTN) are diagnosed solely on the basis of an elevated beta-HCG level. Traditionally, these patients are treated with chemotherapy, but one large observational study suggests that a subset of these patients may be safely observed.",
"   </p>",
"   <p>",
"    For women with",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    GTN solely on the basis of a persistently elevated hCG, we suggest observation, provided they are willing and able to follow a careful schedule of surveillance with blood tests every two weeks. Patients in whom serial hCG evaluations are not possible, who do not demonstrate a normalization of their hCG within 12 months (provided they remain clinically stable without symptoms of GTN), or whose levels continue to rise should undergo definitive treatment. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chemotherapy regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This approach was illustrated in a retrospective analysis involving almost 14,000 women treated for a hydatidiform mole between 1993 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/27\">",
"     27",
"    </a>",
"    ]. Following primary treatment, 92 percent had spontaneous normalization of their hCG levels within six months of evacuation and 7 percent required chemotherapy. Fewer than 1 percent (n=76) had persistently high hCG levels. Of these patients, 66 (87 percent) continued under surveillance and the remaining 13 percent underwent chemotherapy with the following outcomes reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      hCG normalized in 98 percent of patients undergoing continued surveillance. None of these patients developed GTN requiring chemotherapy.",
"     </li>",
"     <li>",
"      Treatment with chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and folinic acid) induced an 80 percent remission rate. Two patients never reached a normal hCG despite chemotherapy, but remained asymptomatic with 3 and 15 years of follow-up.",
"     </li>",
"     <li>",
"      There were no deaths in either group with a median follow-up of 2 years (range, 0.6 to 15 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chemotherapy regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is a major component of curative therapy for the majority of women diagnosed with malignant GTD. As a group, malignant gestational trophoblastic tumors are exquisitely sensitive to chemotherapy, and they represent one of the only cancers for which single agent therapy is still in use. The choice of single agent versus combination chemotherapy depends on risk category, disease stage, and previous drug treatment.",
"   </p>",
"   <p>",
"    What follows is a brief description of the various chemotherapy regimens that are used for treatment of malignant GTD, including efficacy and side effects. Treatment recommendations according to disease stage and prognostic risk score are presented below (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Overview of treatment by stage'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Single-agent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent chemotherapy is widely accepted for low-risk malignant GTD. In the United States, the most commonly used drugs for monotherapy are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    and 5-fluorouracil (5-FU) are other active single agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Methotrexate with and without leucovorin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dramatic cure of women with metastatic choriocarcinoma using single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) was first reported in 1956; at present, it remains a mainstay of single-agent treatment for low-risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTX is commonly given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (folinic acid) for \"rescue\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Leucovorin calcium, an agent that has no inherent antitumor activity, is able to protect against MTX toxicity in normal cells by overcoming the defect in folate metabolism induced by MTX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the doses of MTX commonly used for malignant GTD (50 to 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue is less critical since the use of leucovorin is more important when MTX doses are over 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/32\">",
"     32",
"    </a>",
"    ]. To be maximally effective, leucovorin rescue should be started within 24 hours of MTX dosing; effective rescue is difficult after about 40 hours. One approach is to withhold leucovorin unless measured serum levels of MTX are beyond a threshold value at a certain time after drug administration (eg, 10",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    or higher at 24 hours after infusion of MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Several dosing regimens for single agent MTX with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    are in clinical use, and there is little evidence to support the superiority of any one over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infusional MTX is administered as a single IV bolus dose of MTX 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 30 minutes followed by a 12-hour infusion of MTX 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/33,34,37,38\">",
"       33,34,37,38",
"      </a>",
"      ]. This regimen is associated with minimal toxicity (and no alopecia), but it is somewhat inconvenient. At least some data suggests that use of this regimen is associated with a greater likelihood of needing salvage chemotherapy than the eight-day regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An eight-day regimen of MTX (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IM every other day for four doses) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium (0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      given once, 24 hours after each dose) is easy to administer and well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/38\">",
"       38",
"      </a>",
"      ]. It is associated with remission rates in excess of 90 percent for patients with stage I GTD and approximately 70 percent of those with low-risk stage II or III disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/36,39-42\">",
"       36,39-42",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H28\">",
"       'Overview of treatment by stage'",
"      </a>",
"      below).",
"      <br/>",
"      <br/>",
"      A second course of treatment (either with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or an alternative active single agent), which is required in 10 to 30 percent of patients, can be administered if the serum level of beta-hCG does not fall by one log within 18 days, or if the value plateaus for more than two weeks before returning to normal. (See",
"      <a class=\"local\" href=\"#H52\">",
"       'Monitoring during and after chemotherapy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Acute toxicity with this regimen was addressed in a series of 250 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/41\">",
"       41",
"      </a>",
"      ]. There was no alopecia. Nausea was mild in all cases, and complicated fewer than 15 percent of all treatment cycles, vomiting occurred in less than 5 percent. One-fourth of patients developed grade 1 or 2 mucositis, and an additional one-fourth had grade 1 or 2 blepharitis or conjunctivitis. Hematologic toxicity was mild and infrequent: grade 3 or 4 neutropenia or thrombocytopenia complicated fewer than 1 percent of treatment cycles.",
"     </li>",
"     <li>",
"      A regimen of weekly MTX (30 to 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IM weekly) was developed by the Gynecologic Oncology Group (GOG) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43\">",
"       43",
"      </a>",
"      ]. Treatment is repeated until the serum beta-hCG concentration falls to normal (less than 5",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      for three consecutive weeks.",
"      <br/>",
"      <br/>",
"      This regimen may be similarly effective but less toxic than the eight-day regimen in patients with nonmetastatic malignant GTD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43-45\">",
"       43-45",
"      </a>",
"      ], although few comparative studies have been conducted (see below). In one series, the complete biochemical response rate was 81 percent after a median of seven weeks (range 3 to 19) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43\">",
"       43",
"      </a>",
"      ]. Thirteen of 63 patients developed grade 1 or 2 neutropenia, while three had platelet nadirs below",
"      <span class=\"nowrap\">",
"       140,000/microL.",
"      </span>",
"      There were no other significant toxic effects.",
"      <br/>",
"      <br/>",
"      A randomized GOG study comparing weekly MTX with pulsed biweekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      showed that the complete response rate with weekly MTX was particularly low (9 percent; 1 of 11 patients) for women with high-risk disease (WHO score 5-6) or choriocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/46\">",
"       46",
"      </a>",
"      ]. It should be noted, however, that the MTX dose utilized in this study was 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week, ie, the lowest weekly regimen used in clinical practice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Staging and prognostic stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although significant toxicity with MTX is infrequent, hematologic indices should be carefully monitored during therapy. Normal renal and liver function should be demonstrated prior to each treatment, as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is entirely excreted by the kidney, and it may be hepatotoxic. Furthermore, methotrexate has also been associated with idiopathic interstitial pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H17#H17\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Antimetabolites'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=see_link&amp;anchor=H4164341#H4164341\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Dactinomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older retrospective series suggested that single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    (actinomycin D) was as effective but more toxic than MTX monotherapy when used for initial treatment of patients with low-risk GTD. Over time, five-day regimens (12",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    or 0.5 mg total dose daily for five days, repeated every two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]) have evolved to \"pulsed\" regimens using single higher doses (typically 1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    administered every two weeks. These regimens are less toxic and easier to administer; however, whether they are as effective as the five-day regimen remains a point of controversy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, the five-day regimen was associated with a 94 percent rate of complete and sustained remission in women with nonmetastatic disease; the corresponding value for those with metastatic disease was 67 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar complete remission rate (94 to 100 percent) for nonmetastatic disease was achieved with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      1.25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (or 40",
"      <span class=\"nowrap\">",
"       microgram/kg)",
"      </span>",
"      intravenously every other week in at least two retrospective series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. However, others report a 20 to 40 percent failure rate of initial therapy with biweekly dactinomycin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/46,52,53\">",
"       46,52,53",
"      </a>",
"      ]. In such cases, successful salvage may be accomplished with the alternative five-day dactinomycin regimen or with single agent MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This biweekly regimen was directly compared to single agent MTX (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) in a trial conducted by the GOG in 240 women with &ldquo;low-risk&rdquo; GTN, which included some women with choriocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/46\">",
"       46",
"      </a>",
"      ]. The initial complete response rate was significantly higher with dactinomycin (70 versus 53 percent), an advantage that persisted when the analysis was restricted to women with a WHO score of 0 to 4 and non-choriocarcinoma histology (73 versus 58 percent). The data suggest that pulsed dactinomycin may be more effective than the 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      dose of weekly MTX. However, most women who failed initial treatment received the alternative agent, and in the final analysis, there was only one disease recurrence in each arm. Dactinomycin was associated with significantly more frequent and severe (grade 2) nausea, grade 1 to 2 vomiting, low-grade gastrointestinal tract toxicity, rash and alopecia, and neutropenia. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    to the more commonly used multi-day MTX regimens. At least in the United States, the main use of dactinomycin is for the treatment of MTX-resistant nonmetastatic malignant GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/40,43,48\">",
"     40,43,48",
"    </a>",
"    ]. In this setting, the five consecutive day treatment protocol is preferred given the low remission rates with the single higher dose regimen.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     Dactinomycin",
"    </a>",
"    is considered a highly emetogenic agent, and prophylaxis using modern antiemetic regimens is indicated prior to each dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days every 10 days until remission is achieved) is another effective monotherapy regimen, which is used mainly for salvage of MTX failures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/54\">",
"     54",
"    </a>",
"    ]. Single agent etoposide is also an acceptable option for primary therapy for low-risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/36,55\">",
"     36,55",
"    </a>",
"    ]. Because of the risk of secondary malignancy (leukemia), etoposide is less often used as an upfront regimen than either MTX or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    . However, the risk is low, probably less than 1 percent if the cumulative etoposide dose is &lt;2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     5-Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-fluorouracil (5-FU) has been the preferred single agent for low-risk malignant GTD in China, inducing a complete remission in 93 and 86 percent of patients with stage I or II disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/56\">",
"     56",
"    </a>",
"    ]. Although not standardized, a typical regimen consists of 5-FU 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 10 days, repeated every 28 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    , 1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    biweekly, to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly, has demonstrated a superior response rate for dactinomycin over methotrexate, 69 percent versus 53 percent (p=0.015) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the clinical impact of this trial is limited due to concern about the low dose of MTX.",
"   </p>",
"   <p>",
"    Comparative efficacy of chemotherapy regimens was also evaluated in a retrospective review of 247 patients undergoing single agent therapy for low-risk malignant GTD using one of the following four regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eight-day alternating course of IM MTX with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue (MTX-CF)",
"     </li>",
"     <li>",
"      Five-day IM MTX",
"     </li>",
"     <li>",
"      Five-day IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"     </li>",
"     <li>",
"      Five-day IV infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary remission rate was significantly higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    (90 and 84 percent, respectively) than with either MTX regimen (60 percent with the eight-day regimen and 74 percent with the five-day regimen). However, overall disease-free survival (87 percent) was similar for all regimens, reflecting the success of salvage chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/36\">",
"     36",
"    </a>",
"    ]. Treatment-related toxicity with etoposide and dactinomycin was actually less than that with the MTX regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant GTD is a chemotherapy-sensitive disease. Single agent chemotherapy alone can achieve remission in over 90 percent of patients with stage I disease, and over 80 percent of women with low-risk stage II and III disease (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Overview of treatment by stage'",
"    </a>",
"    below). The definition of remission is three consecutive normal hCG levels over a 14 to 21 day period. (See",
"    <a class=\"local\" href=\"#H52\">",
"     'Monitoring during and after chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The best regimen has not been determined, although some data suggest there is a higher likelihood of requiring further chemotherapy in patients who are treated with the infusional rather than eight day regimen of MTX. Largely based upon the GOG trial discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43\">",
"     43",
"    </a>",
"    ], 2004 guidelines from the American College of Obstetricians and Gynecologists (ACOG) recommend weekly MTX as the treatment of choice until beta-hCG values have reached normal levels, followed by an additional one to two weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16\">",
"     16",
"    </a>",
"    ]. However, broad consensus on this issue is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. Others prefer weekly MTX therapy or pulsed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Multiagent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy is used for disease that is refractory to single-agent therapy, for newly diagnosed high-risk malignant GTD (defined as stage IV disease or stage",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    disease with a high prognostic risk score, (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    )), and for PSTT (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Overview of treatment by stage'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The most commonly used multiagent chemotherapy regimens and the application of these regimens to various clinical settings are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     EMA/CO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the absence of randomized trials to prove its superiority, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    <span class=\"nowrap\">",
"     (EMA/CO)",
"    </span>",
"    has become the preferred regimen for initial treatment of high-risk GTD in most countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. The components of this regimen are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      &mdash; 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV over 30 minutes on days 1 and 2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV push followed by 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV over 12 hours on day 1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       Dactinomycin",
"      </a>",
"      &mdash; 0.5 mg IV bolus on days 1 and 2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      calcium &mdash; 15 mg orally every 12 hours for four doses, starting 24 hours after start of MTX",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      &mdash; 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 8",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      (Oncovin&reg;) &mdash; 1.0",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 8",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The regimen is repeated every two weeks until remission (ie, normalization of beta-hCG and disappearance of all radiographically evident disease), and then generally continued for an additional three cycles (six weeks).",
"   </p>",
"   <p>",
"    The efficacy of",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    was evaluated in a study of 272 women with high-risk malignant GTD, 121 of whom had received prior chemotherapy (86 with chemotherapy-resistant disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/64\">",
"     64",
"    </a>",
"    ]. The overall complete remission rate was 78 percent, but the five-year overall survival rate was 86 percent, reflecting successful salvage of some nonresponders with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination therapy with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Second-line chemotherapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    is a relatively well-tolerated regimen. In a series of 45 patients treated with",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    for high-risk GTD, alopecia was universal, but there was no life-threatening toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/62\">",
"     62",
"    </a>",
"    ]. Grade 3 to 4 hematologic toxicity was seen in less than 2 percent of chemotherapy cycles, and only one patient required a one-week treatment delay because of prolonged neutropenia. Gastrointestinal symptoms were mild; only one patient developed grade 3 toxicity requiring hospitalization. More than one-half retained their fertility.",
"   </p>",
"   <p>",
"    However, in addition to these short-term chemotherapy-related risks, this intensive regimen is associated with a small risk of secondary malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In the above series of 272 women with high-risk disease, five (1.8 percent) developed a secondary malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/64\">",
"     64",
"    </a>",
"    ]. There were two acute myeloid leukemias, two cervical cancers, and one gastric adenocarcinoma.",
"   </p>",
"   <p>",
"    Modifications to the",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    regimen for patients with cerebral metastases are discussed in detail below (see",
"    <a class=\"local\" href=\"#H46\">",
"     'Central nervous system metastases'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     EMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EMA regimen uses the same doses as for the",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    regimen, but without the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    . Although they have never been compared directly in a randomized trial, retrospective series suggest that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    (EMA) may be as effective as",
"    <span class=\"nowrap\">",
"     EMA/CO;",
"    </span>",
"    whether it is less toxic is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two series totaling 77 women with high-risk disease, 74 and 75 percent achieved remission with EMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The toxicity profile differed between the studies, however. In one series, alopecia was nearly universal, grade 4 leukopenia or thrombocytopenia occurred in only 5 and 6 percent of patients, respectively, and nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting were frequent but mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the second report noted a more severe toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/66\">",
"     66",
"    </a>",
"    ]. Grade 2 or worse nausea, emesis, or stomatitis developed in 29, 30 and 37 percent, respectively. Fifty-one percent experienced grade 2 or 3 anemia, 8 percent grade 2 or higher thrombocytopenia and 64 percent had grade 3 or 4 neutropenia; in six cases this was complicated by sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     MAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triple therapy with MAC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [original regimen] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [modified regimen]) was once the preferred first-line treatment for patients with high-risk malignant GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], but this regimen fell out of favor for first-line therapy because of low durable remission rates (in some reports as low as 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The comparative efficacy of",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    versus MAC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) was evaluated in a retrospective review from Korea that compared outcomes among 40 women receiving first-line MAC for high-risk disease and 96 who received",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    (using a weekly rather than every two week regimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/72\">",
"     72",
"    </a>",
"    ]. The remission rate with",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    was 91 percent, and the median number of courses needed to achieve remission was 8.5 (8.5 weeks). In contrast, the remission rate with MAC was 68 percent, and the median number of courses required to achieve remission was 10.7 (32 weeks). Furthermore, there were no treatment-related deaths during",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    compared to seven with MAC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the absence of randomized trials to prove its superiority,",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    has emerged as the regimen of choice for initial treatment of high-risk GTD. The regimen is repeated every two weeks until remission (ie, normalization of beta-hCG and disappearance of all radiographically evident disease), and then generally continued for an additional three cycles (six weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Second-line chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional or salvage chemotherapy is required in approximately 20 to 25 percent of women who are resistant to initial chemotherapy, are intolerant of the upfront regimen, or develop recurrent disease after chemotherapy. Almost all patients with relapsed stage I or low-risk disease, and approximately 60 to 70 percent of those with relapsed high-risk disease, can be successfully salvaged with additional chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/71,73-76\">",
"     71,73-76",
"    </a>",
"    ]. Patients who fail to enter initial remission have a worse outcome (five-year survival 43 percent in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/77\">",
"     77",
"    </a>",
"    ]) than do those who relapse after an initial response.",
"   </p>",
"   <p>",
"    Several regimens have activity in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     MAC and EMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with low-risk disease who are resistant to single-agent therapy are often treated with MAC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) in order to avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and the risk of secondary leukemia (see",
"    <a class=\"local\" href=\"#H20\">",
"     'MAC'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H30\">",
"     'Salvage after single-agent therapy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The modified MAC III regimen consists of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IM on days 1, 3, 5, and 7",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      calcium 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IM, IV, or orally on days 2, 4, 6, and 8",
"     </li>",
"     <li>",
"      Actinomycin 12",
"      <span class=\"nowrap\">",
"       micrograms/kg",
"      </span>",
"      per day IV on days 1 through 5",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV on days 1 through 5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cycles are repeated every 21 days.",
"   </p>",
"   <p>",
"    At our institution, we favor this approach, while others use the EMA regimen in this setting (see",
"    <a class=\"local\" href=\"#H19\">",
"     'EMA'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In contrast, women who relapse after",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    are usually treated with a platinum-based regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/75\">",
"     75",
"    </a>",
"    ]. Taxanes are often incorporated into third-line treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h4\">",
"     EMA/EP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used regimen for patients who are refractory to EMA,",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    or MAC is",
"    <span class=\"nowrap\">",
"     EMA/EP.",
"    </span>",
"    The EMA regimen is different for",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    as compared to",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    in that the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    are administered for one day rather than two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/73,74,78\">",
"     73,74,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV over 12 hours on day 1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       Dactinomycin",
"      </a>",
"      0.5 mg IV bolus on day 1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      calcium 15 mg orally or IM twice daily for four doses, 24 hours after start of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 8",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 12 hours on day 8",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The regimen is repeated every two weeks.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    for salvage therapy was shown in a series of 42 women with",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    gestational trophoblastic neoplasia (GTN) or metastatic placental site trophoblastic tumor (PSTT, n = 8) that was either refractory to or recurred after initial therapy with",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    (see above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/73\">",
"     73",
"    </a>",
"    ]. For the women with GTN, a complete remission was obtained in 21 of 22 who were resistant to previous",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    and who had a nearly normal serum beta-hCG, all 12 who were resistant or relapsed after",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    and had elevated serum beta-hCG concentrations, and all three who relapsed after an initial response to",
"    <span class=\"nowrap\">",
"     EMA/CO.",
"    </span>",
"    Four of the eight patients with PSTT were alive and in remission after",
"    <span class=\"nowrap\">",
"     EMA/EP.",
"    </span>",
"    The cumulative overall survival for all patients was 81 percent.",
"   </p>",
"   <p>",
"    Treatment-related toxicity with this intensive weekly treatment regimen can be prominent. In this report, as an example, rates of grade 3 or 4 anemia, neutropenia and thrombocytopenia were 21, 68, and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/73\">",
"     73",
"    </a>",
"    ]. Cumulative myelosuppression prompted treatment delays in 88 percent and dose reductions in 38 percent. However, hematopoietic growth factor support was only applied to 13 patients (31 percent). Ten patients had multiple grade 3 or 4 toxicities.",
"   </p>",
"   <p>",
"    Low blood cell counts at the beginning of a scheduled subsequent course of chemotherapy do not mandate dose reductions or treatment delays unless the previous cycle was complicated by febrile neutropenia or some other significant clinical event. The use of colony stimulating factors to maintain dose intensity and avoid unnecessary treatment delays is discussed below (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Importance of maintaining dose intensity'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     PVB and PEB",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women resistant to both",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     EMA/EP,",
"    </span>",
"    the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV daily for five days, every three weeks),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV on days 1 and 2, every three weeks), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (30 units IV on day 2, then weekly) (PVB) is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Although durable remissions have been achieved in up to 60 percent of refractory patients, surgery may be needed to remove sites of resistant disease (see below).",
"   </p>",
"   <p>",
"    Another commonly used salvage regimen with a similar degree of efficacy is BEP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 2",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/74,82\">",
"     74,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, treatment-related toxicity is less severe with these regimens than with the intensive weekly",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    regimen. Nevertheless, essentially all patients experience myelosuppression (particularly neutropenia), fatigue, hair loss, and at least mild-to-moderate nausea.",
"   </p>",
"   <p>",
"    As with the EMA-EP regimen, low blood cell counts at the beginning of a scheduled subsequent course of chemotherapy do not mandate dose reductions or treatment delays unless the previous cycle was complicated by febrile neutropenia or some other significant clinical event. The use of colony stimulating factors to maintain dose intensity and avoid unnecessary treatment delays is discussed below (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Importance of maintaining dose intensity'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    -related pulmonary toxicity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other regimens can produce durable remissions in the setting of refractory disease, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      , either alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (VIP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/35,83,84\">",
"       35,83,84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (ICE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High dose 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      is routinely used in Asia for salvage therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/88,89\">",
"       88,89",
"      </a>",
"      ] or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/90-92\">",
"       90-92",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Importance of maintaining dose intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment delay or dose reduction, which is usually prompted by chemotherapy-induced neutropenia, may contribute to tumor resistance and failure of a regimen. Since the goal of therapy is cure of disease, unnecessary treatment delays and dose reductions must be avoided if at all possible. Recombinant hematopoietic growth factors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , G-CSF) are an important tool to maintain adequate dose intensity and to prevent unnecessary dose reductions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the American Society of Clinical Oncology suggest primary prophylaxis using CSFs (ie, prophylactic administration during the first cycle) to prevent the development of febrile neutropenia in patients who have a high risk of febrile neutropenia based upon age, medical history, disease characteristics, and the anticipated myelotoxicity of the regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/93\">",
"     93",
"    </a>",
"    ]. Secondary prophylaxis (administration during a subsequent cycle) is recommended for patients who experience a neutropenic complication (including delayed recovery) in which a reduced dose or treatment delay may compromise disease-free or overall survival, or treatment outcome. The goal of hematopoietic growth factor support is to avoid dose reduction and unnecessary treatment delay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link&amp;anchor=H523774275#H523774275\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, we routinely use G-CSF for secondary and not primary prophylaxis. When it is needed, we suggest the use of G-CSF on days 3 through 6 and 9 through 14 when using",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     EMA/EP,",
"    </span>",
"    and on days 6 through 14 when using",
"    <span class=\"nowrap\">",
"     VIP/ICE,",
"    </span>",
"    PVB or BEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/94\">",
"     94",
"    </a>",
"    ]. Alternatively, a pegylated formulation of G-CSF (pegfilgrastim) is available that has a prolonged half-life. This permits the administration of a single dose rather than daily administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT BY STAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for treatment of malignant GTD vary according to stage and risk status (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Stage I disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall cure rate for patients with nonmetastatic disease is over 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/37,43,95-97\">",
"     37,43,95-97",
"    </a>",
"    ]. The selection of primary therapy for stage I GTN is based upon the patient's desire to preserve fertility. If a woman does not wish to preserve fertility, hysterectomy may be performed, with one course of adjuvant single-agent chemotherapy added for treatment of any occult metastases. Either MTX or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    can be given, although we prefer MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16\">",
"     16",
"    </a>",
"    ]. The addition of chemotherapy after hysterectomy does not increase the risk of perioperative bleeding or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contemporary outcomes can be illustrated by a study of 482 patients treated at the New England Trophoblastic Disease Center (NETDC) for stage I GTN between June 1965 and December 2001; 441 (91.5 percent) achieved complete remission with single-agent chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/37\">",
"     37",
"    </a>",
"    ]. All 41 remaining patients who were resistant to single-agent treatment attained remission with combination chemotherapy.",
"   </p>",
"   <p>",
"    The excellent outcomes among women treated for stage I GTD between 1996 and 1998, and reported to FIGO, are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef70087 \" href=\"mobipreview.htm?18/60/19404\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Salvage after single-agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 9 and 33 percent of patients treated with single-agent chemotherapy for low-risk malignant GTD will require salvage chemotherapy because of either resistance to the first-line drug or intolerable adverse effects. Generally accepted criteria for the definition of resistance to first-line single-agent chemotherapy include any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure of the serum beta-hCG concentration fall by one log within 18 days",
"     </li>",
"     <li>",
"      A plateau or increase in hCG for more than two weeks before normal values are obtained on three consecutive weekly specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43,48\">",
"       43,48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The detection of new metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43,48\">",
"       43,48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women who are resistant to either single-agent MTX or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    , single-agent treatment with the other drug is preferred prior to initiating combination chemotherapy. The efficacy of sequential single-agent therapy was demonstrated in a review of 92 patients with low-risk metastatic malignant GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/96\">",
"     96",
"    </a>",
"    ]. Primary remission was achieved with initial single-agent therapy (primarily MTX) in 67 percent; a second sequential single-agent (usually dactinomycin) was given because of drug resistance in 22 patients (22 percent) or drug toxicity in 10 patients (11 percent). All 92 patients were cured, with only one requiring multiagent chemotherapy.",
"   </p>",
"   <p>",
"    Patients who are resistant to single-agent therapy are often treated with MAC, in order to avoid the long-term risks associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H20\">",
"     'MAC'",
"    </a>",
"    above). Another option is the EMA regimen (see",
"    <a class=\"local\" href=\"#H19\">",
"     'EMA'",
"    </a>",
"    above). Over 90 percent of these patients attain durable remissions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Stage I PSTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of postoperative chemotherapy is more controversial in patients with stage I PSTT. In general, response to chemotherapy is more variable than with other malignant forms of GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9,11,99-102\">",
"     9,11,99-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lack of benefit for chemotherapy in addition to surgery in patients with stage I disease was suggested in a retrospective review of 62 patients with PSTT who were treated in the United Kingdom over a 30-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"     9",
"    </a>",
"    ]. Of the 34 who had stage I disease, treatment consisted of surgery alone in 17 and surgery plus chemotherapy in 16 (one patient had chemotherapy alone after refusing surgery). The chemotherapy regimens were",
"    <span class=\"nowrap\">",
"     EMA/CO,",
"    </span>",
"    <span class=\"nowrap\">",
"     EMA/EP,",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus actinomycin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . The 10-year overall survival was not significantly higher in the group receiving chemotherapy (93 versus 91 percent). The authors concluded that surgery alone was an acceptable strategy for stage I disease, unless there are risk factors for disease recurrence (eg, &gt;48 months since antecedent pregnancy, vascular or deep myometrial invasion, serosal involvement, high mitotic index, or persistently raised postoperative hCG concentration). (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Hysterectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Low-risk stage II and III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with low-risk stage II and III GTN (WHO prognostic score less than or equal to 6, (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    )) are managed with primary single-agent chemotherapy using either MTX or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Single-agent chemotherapy'",
"    </a>",
"    above). Remission rates of 80 percent or higher can be achieved without incurring the toxicity of multiagent therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/47,50\">",
"     47,50",
"    </a>",
"    ]. Long-term survival rates are as high as 84 percent, reflecting the success of salvage therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/23,68,95,97,98,103,104\">",
"     23,68,95,97,98,103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Salvage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for the definition of resistance to first-line single-agent chemotherapy are the same as described above for stage I disease (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Salvage after single-agent therapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Patients who are resistant to single-agent therapy generally receive combination therapy. The MAC regimen, which avoids the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (which is associated with a small risk of leukemia, 1 percent), is commonly utilized in this setting. EMA is another treatment option (see",
"    <a class=\"local\" href=\"#H20\">",
"     'MAC'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'EMA'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Surgical reduction of tumor burden by either hysterectomy or local resection (in women desiring to retain fertility) could be considered for women with low-risk metastatic disease who do not respond to single-agent chemotherapy. This approach is usually considered for women who do not desire future fertility and who have disease seen on imaging of the uterus, particularly if there is evidence of invasion into the myometrium. While salvage combination chemotherapy is still required, this approach might lower the number of chemotherapy courses required for cure (see",
"    <a class=\"local\" href=\"#H38\">",
"     'Role of surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     High-risk stage II and III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with FIGO stage II and III disease and a WHO score of 7 or higher (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    ) are at high risk for chemotherapy resistance and disease recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/12,23,24,105,106\">",
"     12,23,24,105,106",
"    </a>",
"    ]. These patients should be managed with primary combination chemotherapy, typically",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H18\">",
"     'EMA/CO'",
"    </a>",
"    above). In a series of 272 women with high-risk malignant GTD who were treated with",
"    <span class=\"nowrap\">",
"     EMA/CO,",
"    </span>",
"    78 percent entered complete biochemical remission, and only 17 percent developed resistance to",
"    <span class=\"nowrap\">",
"     EMA/CO.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Salvage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional",
"    chemotherapy will be required in approximately 20 to 25 percent of high-risk patients. Patients who are resistant to",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    are most often treated with",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Second-line chemotherapy'",
"    </a>",
"    above). In one study, among women who developed resistance to",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    chemotherapy, successful salvage with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination regimen with or without surgery was possible in 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/64\">",
"     64",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H38\">",
"     'Role of surgery'",
"    </a>",
"    below). As a result of successful salvage therapy, overall survival rates are 90 percent or greater in contemporary series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Stage II/III PSTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage II or III PSTT are usually managed by combined surgery and combination chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Stage IV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage IV disease are a high-risk group with a propensity for rapidly progressive disease and chemoresistance. The use of primary combination chemotherapy in conjunction with selective use of radiation and surgical treatment has resulted in significantly improved remission rates in patients with stage IV disease. Before 1975, only 30 percent of patients with stage IV disease achieved remission. After 1975, when the concept of early intensive multiagent treatment was introduced, a dramatic improvement was observed in the survival of patients with stage IV disease.",
"   </p>",
"   <p>",
"    At present, about 80 percent of patients with stage IV disease achieve an initial disease remission, and 45 to 60 percent maintain a durable remission (",
"    <a class=\"graphic graphic_table graphicRef70087 \" href=\"mobipreview.htm?18/60/19404\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/75,98,107-109\">",
"     75,98,107-109",
"    </a>",
"    ]. Therefore, these patients should all be treated with curative intent.",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    is recommended as initial therapy for patients with stage IV disease (see",
"    <a class=\"local\" href=\"#H18\">",
"     'EMA/CO'",
"    </a>",
"    above). Similar to stage II and III high risk patients, resistant disease is treated primarily with",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Second-line chemotherapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Specific considerations in the treatment of selected metastatic sites (brain, liver, lung and vaginal metastases) are addressed in detail below (see",
"    <a class=\"local\" href=\"#H45\">",
"     'Treatment of selected metastatic sites'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in patients with all stages of malignant GTD is to excise sites of bulky",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistant tumor, and less frequently, to treat complications of the disease such as hemorrhage or bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Uterine evacuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of repeat suction curettage in patients with persistent postmolar GTN is controversial and remains an area of debate. A second curettage may have a debulking effect and possibly lower the number of chemotherapy courses required for cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is increasing interest in the potential for surgery alone as curative treatment for stage I low-risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/105\">",
"     105",
"    </a>",
"    ]. There is some evidence that patients with low-risk stage I disease who undergo a second curettage may not require any chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. However, interpretation of the published literature is difficult because of the varying definitions of persistent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. In our view, repeat curettage is associated with risks of uterine perforation, hemorrhage, infection, intrauterine adhesions, and anesthetic complications, and should only be performed if there is evidence of retained tissue in the uterus.",
"   </p>",
"   <p>",
"    In the case of PSTT, ultrasound imaging may permit differentiation between two types of disease, hypervascular and hypovascular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/11,113\">",
"     11,113",
"    </a>",
"    ]. This is clinically useful because massive bleeding following dilation and curettage has been reported with the hypervascular type. Thus, dilation and curettage should be avoided when there is prominent vascularity within the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with choriocarcinoma who do not desire future fertility, hysterectomy is usually performed before chemotherapy. Hysterectomy prevents the persistence of drug-resistant local disease, and can shorten the duration and amount of chemotherapy required to produce remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/95,114\">",
"     95,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to choriocarcinoma, hysterectomy is the primary therapy for stage I or II PSTT because the tumor is usually limited to the uterus, and the response to chemotherapy is more variable than with other malignant forms of GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9,11,99-102\">",
"     9,11,99-102",
"    </a>",
"    ]. For women at high risk of recurrent disease, adjuvant chemotherapy (generally combination chemotherapy rather than single agent therapy) is warranted. In addition to the presence of overt metastatic disease, other features that suggest high risk include duration greater than two years from an antecedent pregnancy and a high mitotic index (over 5 mitoses per 10 high power fields) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Chemotherapy-resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy should also be considered in the subset of women who have chemotherapy-resistant disease, particularly if the histology is PSTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9,64,74,110,115-120\">",
"     9,64,74,110,115-120",
"    </a>",
"    ]. In such cases, it can contribute to a potential cure: long-term survival has been reported in 70 to 97 percent of cases in small series.",
"   </p>",
"   <p>",
"    In the case of PSTT, additional postoperative chemotherapy should be considered if there is residual tumor in the surgical specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"     9",
"    </a>",
"    ]. In this series, 61 percent of patients with PSTT who were treated with primary chemotherapy showed no or an incomplete response to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"     9",
"    </a>",
"    ]. Long-term disease control was achieved in 12 of 13 patients with only an incomplete response to initial chemotherapy, eight after surgery alone and four after surgery followed by more chemotherapy.",
"   </p>",
"   <p>",
"    Hysterectomy may also be necessary to control uterine bleeding or ongoing sepsis due to infection of necrotic tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Local excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who desire to retain fertility, more conservative surgical therapy may be considered, even in patients with a localized PSTT. Successful treatment of localized disease by hysterotomy, local tumor excision, and uterine reconstruction has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/121\">",
"     121",
"    </a>",
"    ]. Disease localization via ultrasound, MRI,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arteriography is often helpful for planning of local resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Presurgical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven benefit to performing a hysterectomy if the uterus has no radiographically visualized lesions. Thus, radiographic imaging, with magnetic resonance imaging (MRI)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasonography, should be performed in the prehysterectomy evaluation of women being considered for this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, serum beta-hCG concentration usually has to exceed 700",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    to detect myometrial invasion by MRI; thus, false negative results may be obtained in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/122\">",
"     122",
"    </a>",
"    ]. There is also a documented lag time between the fall in serum beta-hCG (tumor regression) and complete radiologic absence of disease. As a result, false positive results can be obtained if imaging is performed too early.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Surgical excision of metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery also has a role in the management of metastatic disease sites (see",
"    <a class=\"local\" href=\"#H45\">",
"     'Treatment of selected metastatic sites'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     TREATMENT OF SELECTED METASTATIC SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Central nervous system metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral metastases are uncommon overall, but they occur in 9 to 21 percent of patients with metastatic GTN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/124,125\">",
"     124,125",
"    </a>",
"    ] Brain metastases are associated with a poorer prognosis than pulmonary or vaginal metastases. In addition, patients who develop brain metastases while on treatment or relapse in the brain after an initial complete remission have a worse prognosis than do those who present with brain metastases before treatment",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/124,126,127\">",
"     124,126,127",
"    </a>",
"    ] Nevertheless, some of these patients can be cured.",
"   </p>",
"   <p>",
"    There are two main therapeutic options for these patients. In the past, institution of whole brain radiotherapy (RT, 20 to 30 Gy in 2 Gy daily fractions) was recommended concurrent with the initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/108,109,124,128,129\">",
"     108,109,124,128,129",
"    </a>",
"    ]. In addition to shrinking the brain metastases, concomitant cranial irradiation increases the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    concentration within the CNS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/130\">",
"     130",
"    </a>",
"    ], reduces the risk of cerebral hemorrhage prior to eradication of tumor, and may improve survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/126,128\">",
"     126,128",
"    </a>",
"    ]. However, the use of concurrent methotrexate and cranial irradiation also increases the likelihood of treatment-related toxicity, especially leukoencephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative is high-dose",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    with or without intrathecal MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/17,75,108,126,131,132\">",
"     17,75,108,126,131,132",
"    </a>",
"    ]. In one study, 30 of 35 patients experienced sustained remission with intensive combination chemotherapy alone that included high-dose intravenous and intrathecal MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical regimen is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/132\">",
"     132",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      &mdash; 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV over 60 minutes on days 1 and 2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV over 24 hours on day 1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       Dactinomycin",
"      </a>",
"      &mdash; 0.5 mg IV bolus on days 1 and 2",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      calcium &mdash; 30 mg IM or orally every 12 hours for three days, starting 32 hours after",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      &mdash; 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 8",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      &mdash; 1.0",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 8",
"     </li>",
"     <li>",
"      Intrathecal MTX &mdash; 12.5 mg total dose on day 8 followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium 15 mg at 24 and 36 hours. The regimen is repeated every two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The higher dose of parenteral MTX allows for adequate levels of MTX within the cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/75,108,131,132\">",
"     75,108,131,132",
"    </a>",
"    ]. The benefit of this approach was shown in a series in which 13 of 15 patients treated with high-dose",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    plus intrathecal MTX achieved a sustained remission without the use of whole brain irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for intrathecal therapy in these patients is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/17,75,107\">",
"     17,75,107",
"    </a>",
"    ]. Although treatment protocols in some institutions omit cranial RT and instead administer intrathecal MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/17,126,133\">",
"     17,126,133",
"    </a>",
"    ], at our institution, high-dose parenteral MTX is preferred over IT MTX and cranial RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Craniotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniotomy is reserved for life-threatening complications (eg, hemorrhage and the need for acute decompression). The incidence of intracranial hemorrhage from metastatic malignant GTD is appreciably higher than with other primary and secondary intracranial neoplasms.",
"   </p>",
"   <p>",
"    Craniotomy and resection of drug-resistant lesions is only rarely required and justified only for patients who do not have metastatic disease elsewhere. In such case, surgery may provide an opportunity for complete remission, even in patients with chemotherapy-resistant brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16,124\">",
"     16,124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 50 percent of women with isolated brain metastases may be cured using either treatment approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/17\">",
"     17",
"    </a>",
"    ]. As a result, concerns for long-term toxicity should be a prime consideration in choosing therapy. The prognosis is poorer if there are coexisting hepatic metastases (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Hepatic metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic metastases present a particularly difficult and challenging problem. Because of the hypervascular nature of these tumors (particularly choriocarcinomas), biopsy may prompt life-threatening hemorrhage.",
"   </p>",
"   <p>",
"    These women also typically have a poor prognosis, even with modern intensive chemotherapy. In one series, the five-year survival rates for women with hepatic metastases alone or in combination with brain metastases were 27 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination chemotherapy can induce a partial response in most women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/135,136\">",
"     135,136",
"    </a>",
"    ]. Hepatic resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    selective embolization or occlusion of the hepatic arteries may be required in selected cases to control bleeding or excise resistant tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/137-139\">",
"     137-139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Pulmonary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;An isolated pulmonary nodule that is resistant to chemotherapy may be treated by thoracotomy with wedge resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/97,140-142\">",
"     97,140-142",
"    </a>",
"    ]. Criteria that predict a favorable outcome from surgical resection include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/117,140,142,143\">",
"     117,140,142,143",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of other systemic metastases",
"     </li>",
"     <li>",
"      Unilateral solitary lung nodule",
"     </li>",
"     <li>",
"      No uterine involvement",
"     </li>",
"     <li>",
"      Urine beta-hCG concentration less than 1000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/140\">",
"       140",
"      </a>",
"      ], serum beta-hCG concentration less than 1500",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/143\">",
"       143",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, prior to proceeding with surgical management, other sites of persistent disease must be ruled out. Often, nonviable fibrotic nodules, which may persist indefinitely after tumor regression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/144\">",
"     144",
"    </a>",
"    ], can be distinguished from viable tumor by PET scan before surgery is contemplated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy is often administered perioperatively, either prior to or after the operation to eradicate any occult metastases and to reduce tumor dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Vaginal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal metastases are usually located on the anterior wall and are friable, vascular, and prone to hemorrhage. They have been reported in 4 to 9 percent of malignant GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. One-third of patients experience significant bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/146,147\">",
"     146,147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleeding from vaginal metastases can be controlled by packing, followed by a wide local excision if necessary. An alternative approach is arteriographic embolization of the vaginal branch of the hypogastric artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718592\">",
"    <span class=\"h2\">",
"     Surgical management of metastases in other intraabdominal organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If chemotherapy has been ineffective in controlling metastatic disease in other organs in the abdomen or pelvis, surgical resection may be considered in selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/18,149,150\">",
"     18,149,150",
"    </a>",
"    ]. In a series of 33 patients undergoing various surgical salvage procedures for chemorefractory GTN, successful surgical salvage was most likely in those who had one preoperative disease site, underwent salvage surgery within one year of initial diagnosis, non-choriocarcinoma histology, and a total WHO prognostic scoring index of &lt;8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/149\">",
"     149",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Staging and prognostic stratification'",
"    </a>",
"    above.) In another report of 61 patients with chemoresistant GTN undergoing surgical salvage, the clinical factors that predicted failure of salvage surgery were age over 35, hCG value &gt;10",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    an antecedent nonmolar pregnancy, and metastases outside of the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/150\">",
"     150",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     MONITORING DURING AND AFTER CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women with GTD should be monitored with serial measurements of serum beta-hCG, beginning at weekly intervals during therapy. The approximate biologic half-life of hCG is 1.5 to 3 days, and serum levels should fall exponentially (by at least one log within 18 days). A slower rate of decline suggests the possibility of chemoresistance, although there is no consensus or clear guideline as to the optimal cutoff for determining chemoresistance or the management of patients with a slower than expected tumor marker decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/38,42,151,152\">",
"     38,42,151,152",
"    </a>",
"    ]. The French Trophoblastic Disease Reference Center in Lyon defines chemotherapy resistance only as an increase or a plateau in two consecutive hCG values over a two-week interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/153\">",
"     153",
"    </a>",
"    ]. As described above, other generally accepted criteria include failure of the serum hCG value to fall by one log within 18 days, and detection of new metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43,48\">",
"     43,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A disease remission requires three consecutive normal hCG values (less than 5",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    over a period of 14 to 21 days. When weekly or biweekly chemotherapy regimens are used, the regimen is continued until the third negative result is obtained. When infusional MTX is given as a one-time dose, hCG levels are then followed weekly, with additional therapy given only if an inadequate response is observed (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Single-agent chemotherapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    After remission is achieved, serum beta-hCG should be measured monthly until monitoring has shown one year of normal hCG levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16\">",
"     16",
"    </a>",
"    ]. Some centers continue biannual titers indefinitely for high-risk individuals, although 85 to 95 percent of recurrences, which are detected as new elevations in serum beta-hCG, occur within the first 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/100,117\">",
"     100,117",
"    </a>",
"    ]. Subgroups that might fit into this high-risk category include women with extreme treatment resistance who required multiple regimens of combination therapy, those with advanced stage choriocarcinoma, particularly with chemoresistance, and patients who have late recurrences.",
"   </p>",
"   <p>",
"    The hCG assay used for monitoring should detect hyperglycosylated hCG, nicked hCG, and nicked hCG missing the C-terminal extension on beta-hCG, as these are the major (and sometimes the only) sources of hCG immunoreactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. Failure to measure these molecules may result in a false negative test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=see_link&amp;anchor=H14#H14\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\", section on 'Human chorionic gonadotropin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;After attaining a normal hCG level, the risk of tumor relapse in women with persistent GTN is 3 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/86\">",
"     86",
"    </a>",
"    ]. The median time from remission to relapse is about six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/22,156\">",
"     22,156",
"    </a>",
"    ]. Many patients with recurrent disease can be cured, and such cases should always be approached with curative intent. The optimal therapy for recurrent disease varies with the initial regimen and responsiveness (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Overview of treatment by stage'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential that women use contraception both during and for the entire duration of beta-hCG follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16\">",
"     16",
"    </a>",
"    ]. Estrogen-progestin contraceptives are preferred because of their low failure rate and relatively low incidence of irregular bleeding, which may confuse the clinical picture. They are both safe and effective in women with GTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/157\">",
"     157",
"    </a>",
"    ]. Intrauterine contraceptive devices are not recommended because of the risk of uterine perforation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     FUTURE PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should be avoided for at least one year following treatment for gestational trophoblastic neoplasia (GTN). As noted above, recurrences are most common within the first year, and the diagnosis of relapse is likely to be delayed in the presence of pregnancy.",
"   </p>",
"   <p>",
"    Pregnancies that occur within six months of completing chemotherapy may be at increased risk of miscarriage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/158\">",
"     158",
"    </a>",
"    ], and possibly stillbirths, and repeat moles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beyond six months, chemotherapy does not generally impact future fertility, the rate of spontaneous abortion or congenital malformations with future pregnancies, or child development following a subsequent term pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/158,160-164\">",
"     158,160-164",
"    </a>",
"    ]. In a report of 445 long-term survivors after chemotherapy for GTN, 97 percent of women who desired fertility after receiving MTX conceived, and 86 percent had at least one live birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/164\">",
"     164",
"    </a>",
"    ]. Women who got three or more drugs were less likely to have a live birth than those who received one or two drugs.",
"   </p>",
"   <p>",
"    Another retrospective cohort study noted no difference in adverse maternal outcomes (spontaneous abortion, repeated mole, spontaneous preterm labor, preeclampsia, placental disease) or in perinatal outcomes (stillbirth, fetal malformation, preterm birth) among women who conceived after receiving combination versus single agent chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/158\">",
"     158",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent disease is more common in patients who have had repeated molar pregnancies (incidence 11 percent after one and 29 percent after two complete or partial moles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/165\">",
"     165",
"    </a>",
"    ]. A repeat molar pregnancy is not, however, necessarily an indication for chemotherapy. In one report, chemotherapy was only necessary in 6 percent of second molar pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/15/42234/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant gestational trophoblastic disease (GTD) is diagnosed when there is clinical, radiologic, pathologic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hormonal evidence of persistent gestational trophoblastic tissue after a gestational event. The spectrum of malignant GTD includes (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Spectrum of disease'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Persistent/invasive",
"      </span>",
"      gestational trophoblastic neoplasia (GTN)",
"     </li>",
"     <li>",
"      Choriocarcinoma",
"     </li>",
"     <li>",
"      Placental site trophoblastic tumor (PSTT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Diagnosis and pretreatment evaluation",
"    </span>",
"   </p>",
"   <p>",
"    The diagnosis of persistent GTN is typically made in women who have persistently elevated serum levels of beta-human chorionic gonadotropin (beta-hCG) following a molar pregnancy. Choriocarcinoma, a highly malignant tumor with the propensity for early dissemination, may develop after any gestational event. The rare PSTT most commonly arises months to years after a term gestation, but can occur after a spontaneous abortion or a molar pregnancy (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In addition to serum levels of beta-hCG, pretreatment evaluation includes pelvic ultrasound and chest imaging. CT or MRI of the brain is recommended in women who have symptoms suggestive of brain metastases, those with vaginal or lung metastases, and in all patients with choriocarcinoma. Prognosis and treatment selection depends on the anatomic extent of disease as well as on clinical factors that are included in the prognostic scoring index (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H6\">",
"     'Staging and pretreatment evaluation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represents our general approach to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94634950\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"   </p>",
"   <p>",
"    For women with",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    gestational trophoblastic neoplasia on the basis of a persistently elevated hCG, we suggest observation after surgery rather than chemotherapy, provided they are willing and able to follow a careful schedule of surveillance with blood tests every two weeks (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Patients in whom serial hCG evaluations are not possible, who do not demonstrate a normalization of their hCG within 12 months, or whose levels continue to rise should undergo definitive treatment as discussed above. (See",
"    <a class=\"local\" href=\"#H933460210\">",
"     'Observation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h3\">",
"     Role of uterine surgery",
"    </span>",
"   </p>",
"   <p>",
"    For women with choriocarcinoma who do not desire future fertility, we suggest hysterectomy in addition to chemotherapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Hysterectomy prevents the persistence of drug-resistant local disease and can shorten the duration and amount of chemotherapy required to produce remission. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Hysterectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For this same reason, we also discuss the option of hysterectomy with women who have",
"    <span class=\"nowrap\">",
"     persistent/invasive",
"    </span>",
"    GTN that is resistant to single agent chemotherapy.",
"   </p>",
"   <p>",
"    For women with choriocarcinoma who wish to preserve future fertility, we administer chemotherapy alone. We suggest local resection after chemotherapy only for those women who have evidence of persistent uterine disease after single agent chemotherapy, especially if there is evidence of myometrial invasion on pelvic ultrasound (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Although these women also receive salvage combination chemotherapy, this approach can shorten the duration and amount of chemotherapy required to produce remission. (See",
"    <a class=\"local\" href=\"#H42\">",
"     'Local excision'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women with stage I and II PSTT, we recommend hysterectomy as the treatment of choice (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). PSTT is usually limited to the uterus, and the response to chemotherapy is more variable than with choriocarcinoma. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Hysterectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hysterectomy may also be indicated in the subset of women who have chemotherapy-resistant disease, particularly if the histology is PSTT. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Chemotherapy-resistant disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, malignant gestational trophoblastic tumors are exquisitely sensitive to chemotherapy, and they represent one of the only cancers for which single-agent therapy is still in use. The exception to this general rule is PSTT, which is less chemotherapy responsive than other types of GTN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h3\">",
"     Assessment of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women with GTD should be monitored with weekly serial measurements of serum beta-hCG during therapy. (See",
"    <a class=\"local\" href=\"#H52\">",
"     'Monitoring during and after chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission is defined as three consecutive normal hCG values (less than 5 milli-international",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      over 14 to 21 days.",
"     </li>",
"     <li>",
"      When weekly or biweekly single agent chemotherapy regimens are used, the regimen is continued until the third negative result is obtained. When infusional MTX is given as a one-time dose, hCG levels are followed weekly, with additional therapy given only if an inadequate response is observed.",
"     </li>",
"     <li>",
"      When combination chemotherapy with",
"      <span class=\"nowrap\">",
"       EMA/CO",
"      </span>",
"      is used, the regimen is repeated every two weeks until normalization of beta-hCG, and then generally continued for an additional three cycles (six weeks).",
"      <br/>",
"      <br/>",
"      After remission is achieved, serum beta-hCG should be measured monthly until monitoring has shown one year of normal hCG levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Management by stage",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h3\">",
"     Stage I",
"    </span>",
"   </p>",
"   <p>",
"    For women with stage I malignant GTD except those with PSTT, we suggest one course of single agent chemotherapy (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Stage I disease'",
"    </a>",
"    above.) We prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    . &nbsp;No clearly superior methotrexate regimen has emerged, although some data suggest there is a higher likelihood of requiring further chemotherapy in women who are treated with the infusional rather than the eight-day regimen. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Single-agent chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If markers remain elevated, or if they do not fall by one log over 18 days, or if they plateau for more than two weeks before returning to normal, we suggest a second course of single-agent therapy rather than combination chemotherapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). We administer a course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was initially used, and methotrexate if dactinomycin was initially given. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Salvage after single-agent therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who are resistant to single-agent therapy, combination chemotherapy is indicated. We suggest MAC rather than",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    to limit the potential for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    -related leukemogenesis (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Second-line chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women with stage I PSTT, hysterectomy is the treatment of choice (see above). We recommend adjuvant chemotherapy after hysterectomy for women who are at high risk for disease recurrence (&gt;48 months since antecedent pregnancy, vascular or deep myometrial invasion, serosal involvement, high mitotic index, or persistently raised postoperative hCG concentration) (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). In such cases, we recommend initial combination rather than single-agent chemotherapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Stage I PSTT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    rather than MAC in this setting (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'EMA/CO'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women who are resistant to",
"    <span class=\"nowrap\">",
"     EMA/CO,",
"    </span>",
"    we recommend a platinum-based regimen such as",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'EMA/EP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h3\">",
"     Stage II and III, WHO score &le;6",
"    </span>",
"   </p>",
"   <p>",
"    For patients with low-risk FIGO stage II and III GTN (WHO prognostic score less than or equal to 6, (",
"    <a class=\"graphic graphic_table graphicRef73235 \" href=\"mobipreview.htm?4/27/4542\">",
"     table 1",
"    </a>",
"    )), we recommend one course of single-agent chemotherapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Low-risk stage II and III disease'",
"    </a>",
"    above.) Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    can be considered for upfront treatment; at our institution, we prefer infusional methotrexate in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rather than dactinomycin. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Single-agent chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women who are resistant to first-line single-agent therapy, we suggest combination chemotherapy rather than a second trial of an alternative single agent (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). We suggest MAC rather than",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    to limit the potential for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    -related leukemogenesis (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Second-line chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women who are resistant to",
"    <span class=\"nowrap\">",
"     EMA/CO,",
"    </span>",
"    we recommend a platinum-based regimen such as",
"    <span class=\"nowrap\">",
"     EMA/EP",
"    </span>",
"    (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'EMA/EP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h3\">",
"     Stage II and III, WHO score &gt;7",
"    </span>",
"   </p>",
"   <p>",
"    For women with high-risk FIGO stage II and III disease (WHO score of 7 or higher) we recommend initial combination rather than single agent chemotherapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). We suggest",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    rather than MAC in this setting (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'EMA/CO'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women who are resistant to",
"    <span class=\"nowrap\">",
"     EMA/CO,",
"    </span>",
"    we recommend a platinum-based regimen (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). At our institution, we use",
"    <span class=\"nowrap\">",
"     EMA/EP.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H24\">",
"     'EMA/EP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h3\">",
"     Stage IV",
"    </span>",
"   </p>",
"   <p>",
"    For women with overt distant metastases, we recommend initial combination chemotherapy rather than single agent chemotherapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). We suggest",
"    <span class=\"nowrap\">",
"     EMA/CO",
"    </span>",
"    rather than MAC in this setting (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'EMA/CO'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As with stage II and III GTD, resistant disease is treated with a platinum-based regimen. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'EMA/EP'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Central nervous system disease",
"      </strong>",
"      <br/>",
"      <br/>",
"      For women who present with cerebral metastases, we suggest high-dose",
"      <span class=\"nowrap\">",
"       EMA/CO",
"      </span>",
"      (with 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of MTX IV) rather than cranial RT or intrathecal MTX (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Central nervous system metastases'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We reserve craniotomy for life-threatening complications and for drug-resistant lesions in patients who have no extracranial disease. (See",
"      <a class=\"local\" href=\"#H47\">",
"       'Craniotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Isolated liver metastases",
"      </strong>",
"      <br/>",
"      <br/>",
"      Biopsy of hepatic metastases should be avoided if at all possible. We reserve hepatic resection for control of bleeding or for excision of resistant tumor. (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Hepatic metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Isolated lung metastases",
"      </strong>",
"      <br/>",
"      <br/>",
"      We restrict thoracotomy and wedge resection to women with chemotherapy-resistant isolated pulmonary metastases who fulfill all of the following criteria (see",
"      <a class=\"local\" href=\"#H50\">",
"       'Pulmonary metastases'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Absence of other systemic metastases",
"     </li>",
"     <li>",
"      Disease limited to one lung",
"     </li>",
"     <li>",
"      No uterine involvement",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/1\">",
"      Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983; 145:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/2\">",
"      Bagshawe KD, Lawler SD, Paradinas FJ, et al. Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 1990; 335:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/3\">",
"      Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 2012; 107:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/4\">",
"      Ayhan A, Tuncer ZS, Halilzade H, K&uuml;&ccedil;&uuml;kali T. Predictors of persistent disease in women with complete hydatidiform mole. J Reprod Med 1996; 41:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/5\">",
"      Driscoll SG. Placental-site chorioma. The neoplasm of the implantation-site trophoblast. J Reprod Med 1984; 29:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/6\">",
"      Feltmate CM, Genest DR, Wise L, et al. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001; 82:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/7\">",
"      Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002; 47:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/8\">",
"      Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006; 100:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/9\">",
"      Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009; 374:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/10\">",
"      Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol 2005; 99:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/11\">",
"      Finkler NJ. Placental site trophoblastic tumor. Diagnosis, clinical behavior and treatment. J Reprod Med 1991; 36:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/12\">",
"      Randall TC, Coukos G, Wheeler JE, Rubin SC. Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy. Gynecol Oncol 2000; 76:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/13\">",
"      Bower M, Paradinas FJ, Fisher RA, et al. Placental site trophoblastic tumor: molecular analysis and clinical experience. Clin Cancer Res 1996; 2:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/14\">",
"      Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med 2002; 47:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/15\">",
"      Gamer EI, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 2004; 49:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/16\">",
"      Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/17\">",
"      Bakri Y, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. J Reprod Med 1994; 39:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/18\">",
"      Soper JT. Identification and management of high-risk gestational trophoblastic disease. Semin Oncol 1995; 22:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/19\">",
"      Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 2001; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/20\">",
"      FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet 2002; 77:285.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. Gestational Trophoblastic Tumors. In: AJCC Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.437.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/22\">",
"      Goldstein DP, Zanten-Przybysz IV, Bernstein MR, Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy. J Reprod Med 1998; 43:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/23\">",
"      DuBeshter B, Berkowitz RS, Goldstein DP, et al. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol 1987; 69:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/24\">",
"      Mortakis AE, Braga CA. \"Poor prognosis\" metastatic gestational trophoblastic disease: the prognostic significance of the scoring system in predicting chemotherapy failures. Obstet Gynecol 1990; 76:272.",
"     </a>",
"    </li>",
"    <li>",
"     Berkowitz RS, Goldstein DP. Gestational trophoblastic diseases. In: Principles and Practice of Gynecologic Oncology, 3rd, Hoskins WJ, Perez CA, Young RC (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000. p.1127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/26\">",
"      Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999; 64:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/27\">",
"      Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet 2012; 379:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/28\">",
"      HERTZ R, LI MC, SPENCER DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956; 93:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/29\">",
"      Kennedy AW. Persistent nonmetastatic gestational trophoblastic disease. Semin Oncol 1995; 22:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/30\">",
"      Homesley HD. Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. J Reprod Med 1998; 43:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/31\">",
"      Goldman ID, Matherly LH. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. NCI Monogr 1987; :17.",
"     </a>",
"    </li>",
"    <li>",
"     Dorr RT, Von Hoff DD. Methotrexate. In: Cancer Chemotherapy Handbook, Dorr RT, Von Hoff DD (Eds), Appleton and Lange, Norwalk, CT 1994. p.694.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/33\">",
"      Wong LC, Ngan HY, Cheng DK, Ng TY. Methotrexate infusion in low-risk gestational trophoblastic disease. Am J Obstet Gynecol 2000; 183:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/34\">",
"      Chan KK, Huang Y, Tam KF, et al. Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2006; 195:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/35\">",
"      Foulmann K, Guastalla JP, Caminet N, et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 2006; 102:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/36\">",
"      Matsui H, Iitsuka Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecol Obstet Invest 1998; 46:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/37\">",
"      Garrett AP, Garner EO, Goldstein DP, Berkowitz RS. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 2002; 47:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/38\">",
"      Growdon WB, Wolfberg AJ, Goldstein DP, et al. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2009; 112:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/39\">",
"      Berkowitz RS, Goldstein DP, Bernstein MR. Methotrexate with citrovorum factor rescue as primary therapy for gestational trophoblastic disease. Cancer 1982; 50:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/40\">",
"      Berkowitz RS, Goldstein DP, Bernstein MR. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/41\">",
"      Khan F, Everard J, Ahmed S, et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 2003; 89:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/42\">",
"      van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/43\">",
"      Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1988; 72:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/44\">",
"      Gleeson NC, Finan MA, Fiorica JV, et al. Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 1993; 14:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/45\">",
"      Kang WD, Choi HS, Kim SM. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2010; 117:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/46\">",
"      Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011; 29:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/47\">",
"      Kohorn EI. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? Gynecol Oncol 2002; 85:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/48\">",
"      McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002; 20:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/49\">",
"      Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975; 36:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/50\">",
"      Petrilli ES, Twiggs LB, Blessing JA, et al. Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 1987; 60:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/51\">",
"      Twiggs LB. Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Gynecol Oncol 1983; 16:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/52\">",
"      Petrilli ES, Morrow CP. Actinomycin D toxicity in the treatment of trophoblastic disease: a comparison of the five-day course to single-dose administration. Gynecol Oncol 1980; 9:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/53\">",
"      Chen LM, Lengyel ER, Bethan Powell C. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol 2004; 94:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/54\">",
"      Mangili G, Garavaglia E, Frigerio L, et al. Management of low-risk gestational trophoblastic tumors with etoposide (VP16) in patients resistant to methotrexate. Gynecol Oncol 1996; 61:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/55\">",
"      Hitchins RN, Holden L, Newlands ES, et al. Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987. Eur J Cancer Clin Oncol 1988; 24:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/56\">",
"      Sung HC, Wu PC, Yang HY. Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. Am J Obstet Gynecol 1984; 150:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/57\">",
"      Song HZ, Yang XY, Xiang Y. Forty-five year's experience of the treatment of choriocarcinoma and invasive mole. Int J Gynaecol Obstet 1998; 60 Suppl 1:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/58\">",
"      Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J Reprod Med 2004; 49:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/59\">",
"      Osborne R, Filiaci V Schink J, et al. A randomized phase III trial comparing parenteral methotrexate and \"pulsed\" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecol Oncol 2008; 108:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/60\">",
"      Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2009; :CD007102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/61\">",
"      Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006; 51:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/62\">",
"      Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 2003; 91:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/63\">",
"      Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013; 1:CD005196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/64\">",
"      Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997; 15:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/65\">",
"      Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996; 14:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/66\">",
"      Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br J Cancer 2000; 82:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/67\">",
"      Matsui H, Suzuka K, Iitsuka Y, et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 2000; 78:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/68\">",
"      Curry SL, Blessing JA, DiSaia PJ, et al. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in \"poor prognosis\" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet Gynecol 1989; 73:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/69\">",
"      Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors. Gynecol Oncol 1984; 19:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/70\">",
"      Jones WB, Cardinale C, Lewis JL Jr. Management of high-risk gestational trophoblastic disease--the Memorial Hospital experience. Int J Gynecol Cancer 1997; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/71\">",
"      El-Lamie IK, El Sayed HM, Badawie AG, et al. Evolution of treatment of high-risk metastatic gestational trophoblastic tumors: Ain Shams University experience. Int J Gynecol Cancer 2006; 16:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/72\">",
"      Kim SJ, Bae SN, Kim JH, et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD. Int J Gynaecol Obstet 1998; 60 Suppl 1:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/73\">",
"      Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/74\">",
"      Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 2005; 97:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/75\">",
"      Newlands ES. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol 2003; 17:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/76\">",
"      Xiang Y, Sun Z, Wan X, Yang X. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J Reprod Med 2004; 49:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/77\">",
"      Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 2007; 96:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/78\">",
"      Newlands ES, Bower M, Holden L, et al. Management of resistant gestational trophoblastic tumors. J Reprod Med 1998; 43:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/79\">",
"      Azab M, Droz JP, Theodore C, et al. Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer 1989; 64:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/80\">",
"      DuBeshter B, Berkowitz RS, Goldstein DP, Bernstein M. Vinblastine, cisplatin and bleomycin as salvage therapy for refractory high-risk metastatic gestational trophoblastic disease. J Reprod Med 1989; 34:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/81\">",
"      Gordon AN, Kavanagh JJ, Gershenson DM, et al. Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer 1986; 58:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/82\">",
"      Willemse PH, Aalders JG, Bouma J, Sleijfer DT. Chemotherapy-resistant gestational trophoblastic neoplasia treated successfully with cisplatin, etoposide, and bleomycin. Obstet Gynecol 1988; 71:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/83\">",
"      Sutton GP, Soper JT, Blessing JA, et al. Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease. Am J Obstet Gynecol 1992; 167:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/84\">",
"      Garris PD, Gallup DG, Melton K. Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide, and cisplatin. Gynecol Oncol 1995; 57:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/85\">",
"      Piamsomboon S, Kudelka AP, Termrungruanglert W, et al. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol 1997; 18:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/86\">",
"      Matsui H, Iitsuka Y, Suzuka K, et al. Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med 2004; 49:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/87\">",
"      Matsui H, Suzuka K, Iitsuka Y, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer 2002; 95:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/88\">",
"      Termrungruanglert W, Kudelka AP, Piamsomboon S, et al. Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Anticancer Drugs 1996; 7:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/89\">",
"      Jones WB, Schneider J, Shapiro F, Lewis JL Jr. Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases. Gynecol Oncol 1996; 61:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/90\">",
"      Osborne R, Covens A, Mirchandani D, et al. Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med 2004; 49:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/91\">",
"      Amikura T, Aoki Y, Banzai C, et al. Metastatic choriocarcinoma successfully treated with paclitaxel and carboplatin after interstitial lung disease induced by EMA-CO. Gynecol Oncol 2006; 102:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/92\">",
"      Shorbagi A, Aksoy S, Kilickap S, G&uuml;ler N. Successful salvage therapy of resistant gestational trophoblastic disease with ifosfamide and paclitaxel. Gynecol Oncol 2005; 97:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/93\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/94\">",
"      Hartenbach EM, Saltzman AK, Carter JR, Twiggs LB. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. Gynecol Oncol 1995; 56:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/95\">",
"      Hammond CB, Weed JC Jr, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol 1980; 136:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/96\">",
"      Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996; 174:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/97\">",
"      Soper JT, Evans AC, Conaway MR, et al. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol 1994; 84:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/98\">",
"      Ngan HY, Odicino F, Maisonneuve P, et al. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/99\">",
"      Gillespie AM, Liyim D, Goepel JR, et al. Placental site trophoblastic tumour: a rare but potentially curable cancer. Br J Cancer 2000; 82:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/100\">",
"      Society of Gynecologic Oncologists Clinical Practice Guidelines. Practice guidelines: gestational trophoblastic disease. Oncology (Williston Park) 1998; 12:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/101\">",
"      Newlands ES, Bower M, Fisher RA, Paradinas FJ. Management of placental site trophoblastic tumors. J Reprod Med 1998; 43:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/102\">",
"      Vardar MA, Altintas A. Placental-site trophoblastic tumor. Principles of diagnosis, clinical behaviour and treatment. Eur J Gynaecol Oncol 1995; 16:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/103\">",
"      Hancock BW, Welch EM, Gillespie AM, Newlands ES. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. Int J Gynecol Cancer 2000; 10:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/104\">",
"      Schink JC, Singh DK, Rademaker AW, et al. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992; 80:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/105\">",
"      Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol 2005; 99:3.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Scientific Group on Gestational Trophoblastic Disease. In: Technical Report Series No. 692, WHO, Geneva, Switzerland 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/107\">",
"      Altinta�� A, Vardar MA. Central nervous system involvement in gestational trophoblastic neoplasia. Eur J Gynaecol Oncol 2001; 22:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/108\">",
"      Small W Jr, Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. Radiology 1996; 200:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/109\">",
"      Schechter NR, Mychalczak B, Jones W, Spriggs D. Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol 1998; 68:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/110\">",
"      Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006; 51:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/111\">",
"      van Trommel NE, Thomas CM, Massuger LF, Sweep FC. Second curettage in persistent trophoblastic disease (PTD): the need for univocal definition of PTD. Gynecol Oncol 2005; 99:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/112\">",
"      Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004; 95:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/113\">",
"      Sumi Y, Ozaki Y, Shindoh N, Katayama H. Placental site trophoblastic tumor: imaging findings. Radiat Med 1999; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/114\">",
"      Suzuka K, Matsui H, Iitsuka Y, et al. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol 2001; 97:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/115\">",
"      Jones WB, Lewis JL Jr. Integration of surgery and other techniques in the management of trophoblastic malignancy. Obstet Gynecol Clin North Am 1988; 15:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/116\">",
"      Jones WB, Wolchok J, Lewis JL Jr. The role of surgery in the management of gestational trophoblastic disease. Int J Gynecol Cancer 1996; 6:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/117\">",
"      Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer 1990; 66:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/118\">",
"      Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol 2002; 87:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/119\">",
"      Doumplis D, Al-Khatib K, Sieunarine K, et al. A review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006. BJOG 2007; 114:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/120\">",
"      Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 2008; 53:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/121\">",
"      Leiserowitz GS, Webb MJ. Treatment of placental site trophoblastic tumor with hysterotomy and uterine reconstruction. Obstet Gynecol 1996; 88:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/122\">",
"      Kohorn EI, McCarthy SM, Taylor KJ. Nonmetastatic gestational trophoblastic neoplasia. Role of ultrasonography and magnetic resonance imaging. J Reprod Med 1998; 43:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/123\">",
"      Ha HK, Jung JK, Jee MK, et al. Gestational trophoblastic tumors of the uterus: MR imaging--pathologic correlation. Gynecol Oncol 1995; 57:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/124\">",
"      Evans AC Jr, Soper JT, Clarke-Pearson DL, et al. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995; 59:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/125\">",
"      Ishizuka T, Tomoda Y, Kaseki S, et al. Intracranial metastasis of choriocarcinoma. A clinicopathologic study. Cancer 1983; 52:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/126\">",
"      Athanassiou A, Begent RH, Newlands ES, et al. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer 1983; 52:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/127\">",
"      Ghaemmaghami F, Behtash N, Memarpour N, et al. Evaluation and management of brain metastatic patients with high-risk gestational trophoblastic tumors. Int J Gynecol Cancer 2004; 14:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/128\">",
"      Yordan EL Jr, Schlaerth J, Gaddis O, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 1987; 69:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/129\">",
"      Cagayan MS, Lu-Lasala LR. Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital. J Reprod Med 2006; 51:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/130\">",
"      Herrington S. Enhancing cure and palliation: radiation therapy in the treatment of metastatic gestational trophoblastic neoplasia. Semin Oncol 1995; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/131\">",
"      Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002; 47:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/132\">",
"      Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989; 7:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/133\">",
"      Wright JD, Mutch DG. Treatment of high-risk gestational trophoblastic tumors. Clin Obstet Gynecol 2003; 46:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/134\">",
"      Crawford RA, Newlands E, Rustin GJ, et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gynaecol 1997; 104:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/135\">",
"      Wong LC, Choo YC, Ma HK. Hepatic metastases in gestational trophoblastic disease. Obstet Gynecol 1986; 67:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/136\">",
"      Bakri YN, Subhi J, Amer M, et al. Liver metastases of gestational trophoblastic tumor. Gynecol Oncol 1993; 48:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/137\">",
"      Grumbine FC, Rosenshein NB, Brereton HD, Kaufman SL. Management of liver metastasis from gestational trophoblastic neoplasia. Am J Obstet Gynecol 1980; 137:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/138\">",
"      Lok CA, Reekers JA, Westermann AM, Van der Velden J. Embolization for hemorrhage of liver metastases from choriocarcinoma. Gynecol Oncol 2005; 98:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/139\">",
"      Barnard DE, Woodward KT, Yancy SG, et al. Hepatic metastases of choriocarcinoma: a report of 15 patients. Gynecol Oncol 1986; 25:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/140\">",
"      Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer 1980; 46:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/141\">",
"      Jones WB, Romain K, Erlandson RA, et al. Thoracotomy in the management of gestational choriocarcinoma. A clinicopathologic study. Cancer 1993; 72:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/142\">",
"      Saitoh K, Harada K, Nakayama H, et al. Role of thoracotomy in pulmonary metastases from gestational choriocarcinoma. J Thorac Cardiovasc Surg 1983; 85:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/143\">",
"      Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008; 53:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/144\">",
"      Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol 2006; 103:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/145\">",
"      Dhillon T, Palmieri C, Sebire NJ, et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med 2006; 51:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/146\">",
"      Yingna S, Yang X, Xiuyu Y, Hongzhao S. Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol Oncol 2002; 84:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/147\">",
"      Berry E, Hagopian GS, Lurain JR. Vaginal metastases in gestational trophoblastic neoplasia. J Reprod Med 2008; 53:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/148\">",
"      Tse KY, Chan KK, Tam KF, Ngan HY. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. J Reprod Med 2007; 52:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/149\">",
"      Lehman E, Gershenson DM, Burke TW, et al. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol 1994; 12:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/150\">",
"      Feng F, Xiang Y, Li L, et al. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia. Gynecol Oncol 2009; 113:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/151\">",
"      You B, Pollet-Villard M, Fronton L, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 2010; 21:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/152\">",
"      Kerkmeijer LG, Thomas CM, Harvey R, et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 2009; 100:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/153\">",
"      Golfier F, Labrousse C, Frappart L, et al. [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. Gynecol Obstet Fertil 2007; 35:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/154\">",
"      Cole LA, Kohorn EI. The need for an hCG assay that appropriately detects trophoblastic disease and other hCG-producing cancers. J Reprod Med 2006; 51:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/155\">",
"      Mitchell H, Bagshawe KD, Newlands ES, et al. Importance of accurate human chorionic gonadotropin measurement in the treatment of gestational trophoblast disease and testicular cancer. J Reprod Med 2006; 51:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/156\">",
"      Ngan HY, Tam KF, Lam KW, Chan KK. Relapsed gestational trophoblastic neoplasia: A 20-year experience. J Reprod Med 2006; 51:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/157\">",
"      Costa HL, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia--a systematic review. Gynecol Oncol 2006; 100:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/158\">",
"      Braga A, Maest&aacute; I, Michelin OC, et al. Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women. Gynecol Oncol 2009; 112:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/159\">",
"      Matsui H, Iitsuka Y, Suzuka K, et al. Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. J Reprod Med 2004; 49:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/160\">",
"      Blagden SP, Foskett MA, Fisher RA, et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer 2002; 86:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/161\">",
"      Berkowitz RS, Tuncer ZS, Bernstein MR, Goldstein DP. Management of gestational trophoblastic diseases: subsequent pregnancy experience. Semin Oncol 2000; 27:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/162\">",
"      Amr MF. Return of fertility after successful chemotherapy treatment of gestational trophoblastic tumors. Int J Fertil Womens Med 1999; 44:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/163\">",
"      Song HZ, Wu PC, Wang YE, et al. Pregnancy outcomes after successful chemotherapy for choriocarcinoma and invasive mole: long-term follow-up. Am J Obstet Gynecol 1988; 158:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/164\">",
"      Rustin GJ, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J (Clin Res Ed) 1984; 288:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/165\">",
"      Garner EI, Lipson E, Bernstein MR, et al. Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor. J Reprod Med 2002; 47:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/15/42234/abstract/166\">",
"      Lorigan PC, Sharma S, Bright N, et al. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol 2000; 78:288.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3242 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42234=[""].join("\n");
var outline_f41_15_42234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H56\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPECTRUM OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Following a molar pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Following a nonmolar pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STAGING AND PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Staging and prognostic stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H501922995\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933460210\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chemotherapy regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Single-agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Methotrexate with and without leucovorin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dactinomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Etoposide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      5-Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Multiagent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EMA/CO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MAC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Second-line chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MAC and EMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EMA/EP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PVB and PEB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Importance of maintaining dose intensity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OVERVIEW OF TREATMENT BY STAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Stage I disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Salvage after single-agent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Stage I PSTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Low-risk stage II and III disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Salvage therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      High-risk stage II and III disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Salvage therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Stage II/III PSTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Stage IV disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ROLE OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Uterine evacuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Chemotherapy-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Local excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Presurgical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Surgical excision of metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      TREATMENT OF SELECTED METASTATIC SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Central nervous system metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Craniotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Hepatic metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Pulmonary metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Vaginal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H718592\">",
"      Surgical management of metastases in other intraabdominal organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      MONITORING DURING AND AFTER CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      FUTURE PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Diagnosis and pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94634950\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      - Role of uterine surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      - Assessment of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Management by stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      - Stage I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      - Stage II and III, WHO score &le;6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      - Stage II and III, WHO score &gt;7",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      - Stage IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/27/4542\" title=\"table 1\">",
"      Staging gest trop neoplas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/2/14382\" title=\"table 2\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/60/19404\" title=\"table 3\">",
"      Gest troph neopl survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23015?source=related_link\">",
"      Gestational trophoblastic disease: Management of hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_15_42235="Indications electrophys study";
var content_f41_15_42235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for cardiac electrophysiologic study",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis and management of bradyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To acquire corroborative data in symptomatic patients with episodic bradyarrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To define the level of atrioventricular (AV) conduction abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis and management of tachyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To define the mechanism of narrow-complex tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To define the mechanism of wide-complex tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To reproduce the clinically documented narrow or wide-complex tachycardia for mapping and transcatheter ablation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Syncope of unknown etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To assess the sinus node function, the AV conduction, and to",
"search for inducible sustained ventricular tachyarrhythmias in patients",
"with syncope and organic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary prevention protocols",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To search for electrophysiologic-induced ventricular",
"tachycardia (VT) or ventricular fibrillation (VF) in patients with",
"coronary disease, depressed ventricular function, and nonsustained VT",
"who are candidates forimplantable cardioverter/defibrillator (ICD)",
"therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous uses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To select optimal ICD parameters for ICD therapy in patients with VT/VF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To assess the effect of cardiac surgery, eg, coronary revascularization, endocardial resection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rarely to assess the modifying (suppressive) effect of an",
"antiarrhythmic drug in patients with VT, VF, or supraventricular",
"tachycardia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42235=[""].join("\n");
var outline_f41_15_42235=null;
var title_f41_15_42236="TNM gastrointest carcinoid";
var content_f41_15_42236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for carcinoid tumors of the small bowel and ampulla of Vater",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades lamina propria or submucosa and size 1 cm or less* (small intestinal tumors); tumor 1 cm or less (ampullary tumors)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades muscularis propria or size &gt;1 cm (small intestinal tumors); tumor &gt;1 cm (ampullary tumors)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal tumors) or invades pancreas or retroperitoneum (ampullary or duodenal tumors) or into non-peritonealized tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades visceral peritoneum (serosa) or invades other organs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       For any T, add (m) for multiple tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastases (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIA",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Tumor limited to ampulla of Vater for ampullary gangliocytic paraganglioma.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42236=[""].join("\n");
var outline_f41_15_42236=null;
var title_f41_15_42237="Inverse psoriasis PI";
var content_f41_15_42237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 145px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inverse psoriasis of the axilla (armpit) is characterized by erythema without visible scaling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42237=[""].join("\n");
var outline_f41_15_42237=null;
var title_f41_15_42238="Rocker sole shoe";
var content_f41_15_42238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Rocker sole shoe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42238=[""].join("\n");
var outline_f41_15_42238=null;
var title_f41_15_42239="Afferent pupillary defect";
var content_f41_15_42239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left afferent pupillary defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left pupil is the same size as the right under all conditions of illumination because the efferent pathways are intact, but both pupils are smaller when light is directed at the right eye than when it is directed at the left eye, because light is detected better by the right eye. Alternate swinging of the light between the two eyes therefore produces dilation each time the light is directed to the left eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Gelb DJ. The Neurologic Examination. In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_15_42239=[""].join("\n");
var outline_f41_15_42239=null;
